<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">F1000Res</journal-id>
<journal-id journal-id-type="iso-abbrev">F1000Res</journal-id>
<journal-id journal-id-type="pmc">F1000Research</journal-id>
<journal-title-group>
<journal-title>F1000Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-1402</issn>
<publisher>
<publisher-name>F1000 Research Limited</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29333255</article-id>
<article-id pub-id-type="pmc">5749125</article-id>
<article-id pub-id-type="doi">10.12688/f1000research.11243.1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group>
<subject>Articles</subject>
<subj-group>
<subject>Aging</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>In vivo</italic> genome editing in animals using AAV-CRISPR system: applications to translational research of human disease</article-title>
<fn-group content-type="pub-status">
<fn>
<p>[version 1; referees: 2 approved]</p>
</fn>
</fn-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lau</surname>
<given-names>Cia-Hin</given-names>
</name>
<xref ref-type="corresp" rid="c1">a</xref>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suh</surname>
<given-names>Yousin</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4528-0363</contrib-id>
<xref ref-type="corresp" rid="c2">b</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<aff id="a1">
<label>1</label>Department of Mechanical and Biomedical Engineering, City University of Hong Kong, Hong Kong, SAR, China</aff>
<aff id="a2">
<label>2</label>Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, USA</aff>
<aff id="a3">
<label>3</label>Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, New York, USA</aff>
<aff id="a4">
<label>4</label>Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA</aff>
<aff id="a5">
<label>5</label>Institute for Aging Research, Albert Einstein College of Medicine, Bronx, New York, USA</aff>
</contrib-group>
<author-notes>
<corresp id="c1">
<label>a</label>
<email xlink:href="mailto:lauciahin_4275@yahoo.com">lauciahin_4275@yahoo.com</email>
</corresp>
<corresp id="c2">
<label>b</label>
<email xlink:href="mailto:yousin.suh@einstein.yu.edu">yousin.suh@einstein.yu.edu</email>
</corresp>
<fn fn-type="COI-statement">
<p>No competing interests were disclosed.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>6</volume>
<elocation-id>2153</elocation-id>
<history>
<date date-type="accepted">
<day>14</day>
<month>12</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2017 Lau CH and Suh Y</copyright-statement>
<copyright-year>2017</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="f1000research-6-12130.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Adeno-associated virus (AAV) has shown promising therapeutic efficacy with a good safety profile in a wide range of animal models and human clinical trials. With the advent of clustered regulatory interspaced short palindromic repeat (CRISPR)-based genome-editing technologies, AAV provides one of the most suitable viral vectors to package, deliver, and express CRISPR components for targeted gene editing. Recent discoveries of smaller Cas9 orthologues have enabled the packaging of Cas9 nuclease and its chimeric guide RNA into a single AAV delivery vehicle for robust
<italic>in vivo</italic> genome editing. Here, we discuss how the combined use of small Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration has advanced the development of efficient and precise
<italic>in vivo</italic> genome editing and comprehensively review the various AAV-CRISPR systems that have been effectively used in animals. We then discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss ongoing non-viral-based
<italic>ex vivo</italic> gene therapy clinical trials to underscore the current challenges and future prospects of CRISPR/Cas9 delivery for human therapeutics.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>CRISPR/Cas9 complex</kwd>
<kwd>genome editing</kwd>
<kwd>adeno-associated virus</kwd>
</kwd-group>
<funding-group>
<award-group id="fund-1">
<funding-source>National Institutes of Health</funding-source>
<award-id>AG017242</award-id>
<award-id>GM104459</award-id>
<award-id>CA180126</award-id>
</award-group>
<funding-statement>This work was funded by National Institutes of Health grants AG017242, GM104459, and CA180126 (to Yousin Suh). </funding-statement>
</funding-group>
</article-meta>
<notes>
<sec sec-type="editor-note">
<title>Editorial Note on the Review Process</title>
<p>
<ext-link ext-link-type="uri" xlink:href="http://f1000research.com/browse/f1000-faculty-reviews">F1000 Faculty Reviews</ext-link> are commissioned from members of the prestigious
<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty">F1000 Faculty</ext-link> and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).</p>
<p>The referees who approved this article are: </p>
<list list-content="reviewer-list" list-type="simple">
<list-item>
<p>
<named-content content-type="reviewer-name">Dirk Grimm</named-content>, Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
<list-item>
<p>
<named-content content-type="reviewer-name">Jin-Soo Kim</named-content>, Department of Chemistry, Seoul National University, Seoul, 151-742, Korea, South
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
</list>
</sec>
</notes>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>CRISPR (clustered regulatory interspaced short palindromic repeat)/Cas9-based RNA-guided DNA endonuclease is transforming biomedical science research and has quickly become the preferred genome-editing platform for interrogating endogenous gene function
<italic>in vivo</italic>
<sup><xref ref-type="bibr" rid="ref-1">1</xref>,
<xref ref-type="bibr" rid="ref-2">2</xref></sup>. The CRISPR-based genome-editing tool has revolutionized the gene-editing technique because of its simplicity in target design, affordability, high efficiency, versatility, and multiplexing capability
<sup><xref ref-type="bibr" rid="ref-3">3</xref></sup>. The commonly used CRISPR system can be implemented in mammalian cells by co-expressing Cas9 nuclease along with chimeric guide RNA (gRNA), which is derived from a synthetic fusion of the CRISPR RNA array (crRNA) and trans-activating crRNA (tracrRNA)
<sup><xref ref-type="bibr" rid="ref-3">3</xref></sup>. The target site sequence of gRNA needs to be immediately followed by an optimal protospacer adjacent motif (PAM) sequence according to the species-derived Cas9 nuclease used at the 3′ end
<sup><xref ref-type="bibr" rid="ref-4">4</xref>,
<xref ref-type="bibr" rid="ref-5">5</xref></sup>. The background of and the recent developments in the CRISPR-based targeted genome-editing toolboxes have been extensively reviewed recently
<sup><xref ref-type="bibr" rid="ref-1">1</xref>,
<xref ref-type="bibr" rid="ref-2">2</xref>,
<xref ref-type="bibr" rid="ref-6">6</xref></sup>. Various applications of CRISPR technologies for genome engineering and medical research have also been reviewed recently
<sup><xref ref-type="bibr" rid="ref-2">2</xref>,
<xref ref-type="bibr" rid="ref-6">6</xref>,
<xref ref-type="bibr" rid="ref-7">7</xref></sup>.</p>
<p>The CRISPR/Cas9 complex can be introduced into the cell in the forms of DNA, messenger RNA (mRNA), or protein
<sup><xref ref-type="bibr" rid="ref-8">8</xref></sup>. The DNA encoding Cas9 and gRNA can be delivered into the cell using the plasmid and viral expression vectors
<sup><xref ref-type="bibr" rid="ref-8">8</xref></sup>. Through microinjection, liposome-mediated transfection, electroporation, or nucleofection
<sup><xref ref-type="bibr" rid="ref-9">9</xref></sup>, several recent studies have shown that the delivery format of active Cas9 protein/gRNA ribonucleoprotein (RNP) complex has lower off-target effects due to rapid clearance of RNPs from the cell
<sup><xref ref-type="bibr" rid="ref-8">8</xref>–
<xref ref-type="bibr" rid="ref-10">10</xref></sup> and rapid gene editing as they cleave chromosomal DNA almost immediately after delivery
<sup><xref ref-type="bibr" rid="ref-9">9</xref>,
<xref ref-type="bibr" rid="ref-10">10</xref></sup> as compared with plasmid DNA transfection. However, the delivery formats of mRNA and protein pose certain technical challenges
<italic>in vivo</italic>. For example, many of the genetic brain disorders affect very large brain areas and more than a single structure in the brain
<sup><xref ref-type="bibr" rid="ref-11">11</xref></sup>. Therefore, global gene delivery to the central nervous system is a key to achieve effective therapies for neurological disorders. Although a recent study has successfully demonstrated genome editing in the mouse brain by local delivery of RNPs
<sup><xref ref-type="bibr" rid="ref-12">12</xref></sup>, it is technically challenging to deliver the RNPs globally to the central nervous system. Thus, the viral-based
<italic>in vivo</italic> genome editing remains a popular choice to achieve stable or elevated expression of Cas9 and single-guide RNA (sgRNA) required for establishing animal disease models and therapeutic gene editing in animals. Indeed, it has been demonstrated that systemic delivery of adeno-associated virus (AAV) vectors enabled uniform and broad vector distribution, and subsequently led to extensive and widespread transgene expression in the adult mouse central nervous system
<sup><xref ref-type="bibr" rid="ref-13">13</xref>–
<xref ref-type="bibr" rid="ref-15">15</xref></sup>.</p>
<p>Animal models are preferred over cell models, as they help understand disease mechanisms at the physiological and systemic levels. Somatic mutagenesis via
<italic>in vivo</italic> genome editing provides an ideal platform to accelerate the generation of transgenic animals for rapid exploration of human diseases and correcting genetic defects in gene therapy.
<italic>In vivo</italic> genome editing also avoids laborious germline targeting and high costs of maintaining transgenic neonates through adulthood in animals with a long life span. Obviously, somatic mutagenesis in adult animals has proven technically more challenging than gene editing of one-cell-stage embryos or zygotes or pluripotent stem cells. The major hurdle is to efficiently deliver the CRISPR components
<italic>in vivo</italic>. To date, various viral, non-viral (for example, lipid nanoparticles), and physical (for example, hydrodynamic injection) based delivery approaches of the CRISPR/Cas9 complex have been adopted for
<italic>in vivo</italic> genome editing. The pros and cons of these delivery methods have been extensively reviewed recently
<sup><xref ref-type="bibr" rid="ref-16">16</xref>–
<xref ref-type="bibr" rid="ref-18">18</xref></sup>.</p>
<p>Given the great potential of viral vectors in gene and cell therapy, five major classes of viral vectors—retroviruses
<sup><xref ref-type="bibr" rid="ref-19">19</xref></sup>, lentiviruses
<sup><xref ref-type="bibr" rid="ref-20">20</xref>,
<xref ref-type="bibr" rid="ref-21">21</xref></sup>, adenoviruses
<sup><xref ref-type="bibr" rid="ref-22">22</xref>,
<xref ref-type="bibr" rid="ref-23">23</xref></sup>, AAVs
<sup><xref ref-type="bibr" rid="ref-24">24</xref>,
<xref ref-type="bibr" rid="ref-25">25</xref></sup>, and baculoviruses
<sup><xref ref-type="bibr" rid="ref-26">26</xref>,
<xref ref-type="bibr" rid="ref-27">27</xref></sup>—have been employed to deliver CRISPR components into mammalian cells for targeted genome editing. The advantages and disadvantages of using these viral vectors for
<italic>in vivo</italic> delivery of the CRISPR transgenes have been extensively reviewed
<sup><xref ref-type="bibr" rid="ref-24">24</xref>,
<xref ref-type="bibr" rid="ref-28">28</xref>–
<xref ref-type="bibr" rid="ref-30">30</xref></sup>. In
<xref ref-type="table" rid="T1">Table 1</xref>, we listed general characteristics and applications of various viral delivery vectors. Among these, the AAV vector is the overall focus of this review. The AAV system provides major advantages for research and therapeutics, including a very mild immune response and toxicity elicited by AAV in animal models. Moreover, AAVs remain primarily episomal upon transduction, avoiding random integration of the viral genetic materials into the host genome that can disrupt neighboring gene function and cause insertional mutagenesis
<sup><xref ref-type="bibr" rid="ref-31">31</xref></sup>. Indeed, there has been no reported case of disease caused by AAV in humans
<sup><xref ref-type="bibr" rid="ref-31">31</xref></sup>. Additionally, AAV can exist long-term as concatemers in non-dividing cells for stable transgene expressions
<sup><xref ref-type="bibr" rid="ref-31">31</xref></sup>. Given a good safety profile of AAV and therapeutic efficacy in a wide range of animal models and human clinical trials (ClinicalTrials.gov), AAV is thought to be one of the most suitable viral vectors for gene therapeutic applications and gene transfer
<italic>in vivo</italic>. Furthermore, there is a wide range of AAV serotypes that can be selected to infect specific tissues
<italic>in vivo</italic>. For these reasons, here, we provide an overview of the state of the art of various AAV-CRISPR systems as well as their principal vector designs for
<italic>in vivo</italic> genome editing in animals. Senís and colleagues were amongst the first to exploit and demonstrate the use of the AAV vectors to package, deliver, and express CRISPR components for targeted gene editing in hard-to-transfect cells and the liver of adult mice
<sup><xref ref-type="bibr" rid="ref-32">32</xref></sup>. Subsequently, an increasing number of the studies used AAV vectors to deliver the CRISPR components into animals for
<italic>in vivo</italic> genome editing. Of note, for certain applications such as packaging of a very large transgene
<sup><xref ref-type="bibr" rid="ref-29">29</xref>,
<xref ref-type="bibr" rid="ref-33">33</xref></sup>, genome-wide screening
<sup><xref ref-type="bibr" rid="ref-20">20</xref>,
<xref ref-type="bibr" rid="ref-34">34</xref>,
<xref ref-type="bibr" rid="ref-35">35</xref></sup>, and production of vaccines and recombinant proteins
<sup><xref ref-type="bibr" rid="ref-36">36</xref>,
<xref ref-type="bibr" rid="ref-37">37</xref></sup>, the other viral vectors may be a better option. However, in-depth discussions of the other viral delivery vehicles for the CRISPR components are beyond the scope of this review.</p>
<table-wrap id="T1" orientation="portrait" position="anchor">
<label>Table 1. </label>
<caption>
<title>Viral delivery vectors for the CRISPR/Cas9 complex.</title>
</caption>
<table content-type="article-table" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Characteristics for a typical
<break></break>vector</th>
<th align="left" colspan="1" rowspan="1" valign="top">Retrovirus
<sup><xref ref-type="bibr" rid="ref-19">19</xref>,
<xref ref-type="bibr" rid="ref-38">38</xref>,
<xref ref-type="bibr" rid="ref-39">39</xref></sup>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">Lentivirus
<sup><xref ref-type="bibr" rid="ref-20">20</xref>,
<xref ref-type="bibr" rid="ref-21">21</xref>,
<xref ref-type="bibr" rid="ref-38">38</xref>,
<xref ref-type="bibr" rid="ref-40">40</xref>,
<xref ref-type="bibr" rid="ref-41">41</xref></sup>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">Adenovirus
<sup><xref ref-type="bibr" rid="ref-22">22</xref>,
<xref ref-type="bibr" rid="ref-42">42</xref>–
<xref ref-type="bibr" rid="ref-48">48</xref></sup>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">Adeno-associated
<break></break>virus
<sup><xref ref-type="bibr" rid="ref-30">30</xref>,
<xref ref-type="bibr" rid="ref-32">32</xref>,
<xref ref-type="bibr" rid="ref-49">49</xref>–
<xref ref-type="bibr" rid="ref-52">52</xref></sup>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">Baculovirus
<sup><xref ref-type="bibr" rid="ref-27">27</xref>,
<xref ref-type="bibr" rid="ref-29">29</xref>,
<xref ref-type="bibr" rid="ref-53">53</xref></sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Common viral type</td>
<td align="left" colspan="1" rowspan="1" valign="top">γ-retroviruses</td>
<td align="left" colspan="1" rowspan="1" valign="top">HIV-1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ad5</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AcMNPV</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Viral envelope</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleocapsid shape</td>
<td align="left" colspan="1" rowspan="1" valign="top">Icosahedral</td>
<td align="left" colspan="1" rowspan="1" valign="top">Icosahedral</td>
<td align="left" colspan="1" rowspan="1" valign="top">Icosahedral</td>
<td align="left" colspan="1" rowspan="1" valign="top">Icosahedral</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rod</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Viral size</td>
<td align="left" colspan="1" rowspan="1" valign="top">80–130 nm</td>
<td align="left" colspan="1" rowspan="1" valign="top">80–130 nm</td>
<td align="left" colspan="1" rowspan="1" valign="top">70–105 nm</td>
<td align="left" colspan="1" rowspan="1" valign="top">18–26 nm</td>
<td align="left" colspan="1" rowspan="1" valign="top">250–300 nm
<break></break>30–60 nm</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Viral genome structure</td>
<td align="left" colspan="1" rowspan="1" valign="top">Linear ssRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Linear ssRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Linear dsDNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Linear ssDNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Circular dsDNA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Viral genome size</td>
<td align="left" colspan="1" rowspan="1" valign="top">8.3 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">9.7 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">36 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">4.7 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">80–180 kb</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Packaging capacity</td>
<td align="left" colspan="1" rowspan="1" valign="top">&lt;8.0 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">&lt;8.0 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">&lt;30 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">&lt;4.5 kb</td>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;38 kb</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Transgene is flanked by</td>
<td align="left" colspan="1" rowspan="1" valign="top">LTRs</td>
<td align="left" colspan="1" rowspan="1" valign="top">LTRs</td>
<td align="left" colspan="1" rowspan="1" valign="top">ITRs</td>
<td align="left" colspan="1" rowspan="1" valign="top">ITRs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tn7s</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Viral generation approach</td>
<td align="left" colspan="1" rowspan="1" valign="top">Triple-plasmid transfection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Triple-plasmid transfection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Homologous recombination</td>
<td align="left" colspan="1" rowspan="1" valign="top">Triple-plasmid transfection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Site-specific transposition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Competent cell used</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stbl3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stbl3</td>
<td align="left" colspan="1" rowspan="1" valign="top">AdEasier-1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stbl3</td>
<td align="left" colspan="1" rowspan="1" valign="top">DH10Bac</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Host cells used</td>
<td align="left" colspan="1" rowspan="1" valign="top">HEK293T</td>
<td align="left" colspan="1" rowspan="1" valign="top">HEK293T</td>
<td align="left" colspan="1" rowspan="1" valign="top">HEK293T or HER911</td>
<td align="left" colspan="1" rowspan="1" valign="top">HEK293T</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sf9 or Sf21</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cells infected</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dividing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dividing or non-dividing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dividing or non-dividing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dividing or non-dividing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dividing or non-dividing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Transduction efficiency</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate</td>
<td align="left" colspan="1" rowspan="1" valign="top">High</td>
<td align="left" colspan="1" rowspan="1" valign="top">Very high</td>
<td align="left" colspan="1" rowspan="1" valign="top">High</td>
<td align="left" colspan="1" rowspan="1" valign="top">High</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Transgene expression</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stable</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stable</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transient</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transient</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transient</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Immune response</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low</td>
<td align="left" colspan="1" rowspan="1" valign="top">High</td>
<td align="left" colspan="1" rowspan="1" valign="top">Very low</td>
<td align="left" colspan="1" rowspan="1" valign="top">Very low</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Toxicity</td>
<td align="left" colspan="1" rowspan="1" valign="top">High</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate</td>
<td align="left" colspan="1" rowspan="1" valign="top">High</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Random genome integration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
<td align="left" colspan="1" rowspan="1" valign="top">Generally no
<break></break>(recombinant AAV has a low
<break></break>frequency of host genome
<break></break>integration events)</td>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Biosafety levels</td>
<td align="left" colspan="1" rowspan="1" valign="top">BSL-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">BSL-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">BSL-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">BSL-1</td>
<td align="left" colspan="1" rowspan="1" valign="top">BSL-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Common applications</td>
<td align="left" colspan="1" rowspan="1" valign="top">Generating stable cell and
<break></break>gene transfer, cancer and
<break></break>stem cell research</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transduce difficult-to-
<break></break>transfect cell, genome-
<break></break>wide screens</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vaccine production, cancer
<break></break>immune therapy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene delivery
<italic>in vivo</italic>,
<break></break>optogenetics</td>
<td align="left" colspan="1" rowspan="1" valign="top">Recombinant proteins
<break></break>and vaccine production</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Clinical trials</td>
<td align="left" colspan="1" rowspan="1" valign="top">Very popular</td>
<td align="left" colspan="1" rowspan="1" valign="top">Very popular</td>
<td align="left" colspan="1" rowspan="1" valign="top">Popular</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increasing popularity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Growing interest</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">First
<italic>ex vivo</italic> gene transfer
<break></break>clinical trial started (disease,
<break></break>ClinicalTrials.gov ID)</td>
<td align="left" colspan="1" rowspan="1" valign="top">1990
<break></break>(severe combined
<break></break>immunodeficiency,
<break></break>NCT00001255)</td>
<td align="left" colspan="1" rowspan="1" valign="top">2007
<break></break>(lymphoma, NCT00569985)</td>
<td align="left" colspan="1" rowspan="1" valign="top">2000
<break></break>(hepatocellular carcinoma,
<break></break>NCT00300521)</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">First
<italic>in vivo</italic> gene transfer
<break></break>clinical trial started (disease,
<break></break>ClinicalTrials.gov ID)</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
<td align="left" colspan="1" rowspan="1" valign="top">2014
<break></break>(sickle cell anemia,
<break></break>NCT02186418)</td>
<td align="left" colspan="1" rowspan="1" valign="top">1993
<break></break>(cystic fibrosis, NCT00004779)</td>
<td align="left" colspan="1" rowspan="1" valign="top">1999
<break></break>(cystic fibrosis, NCT00004533)</td>
<td align="left" colspan="1" rowspan="1" valign="top">None</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AcMNPV, autographa californica multicapsid nucleopolyhedrovirus; HIV, human immunodeficiency virus; ITR, inverted terminal repeat; LTR, long terminal repeat; Tn7, transposon 7.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Here, we aim to review various AAV-CRISPR systems recently demonstrated in mice and to discuss how the combined use of tissue-specific minimal promoters, AAV serotypes, different routes of administration, and small Cas9 orthologues has enabled investigators to achieve maximal efficiency and specificity for
<italic>in vivo</italic> genome editing. In addition, we discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss the promises and hurdles associated with ongoing
<italic>ex vivo</italic> gene therapy clinical trials.</p>
</sec>
<sec>
<title>AAV-CRISPR-based
<italic>in vivo</italic> genome editing in mice</title>
<p>At least 33 published studies successfully used CRISPR/Cas9 alongside AAV vectors for
<italic>in vivo</italic> genome editing in mice (
<xref ref-type="table" rid="T2">Table 2</xref>). The AAV-CRISPR system is particularly useful for editing disease-associated genes in the brain or central nervous system of mice because of the inability of most cationic nanocarriers to cross the blood-brain barrier, high transduction efficiency of AAV vectors in the brain, and non-dividing properties of neurons for long-term therapeutic effects. The AAV-CRISPR system has also been successfully used to restore the gene function in muscle-associated diseases such as Duchenne muscular dystrophy
<sup><xref ref-type="bibr" rid="ref-54">54</xref>–
<xref ref-type="bibr" rid="ref-57">57</xref></sup> and diseases associated with the eye
<sup><xref ref-type="bibr" rid="ref-5">5</xref>,
<xref ref-type="bibr" rid="ref-58">58</xref>–
<xref ref-type="bibr" rid="ref-60">60</xref></sup>, liver
<sup><xref ref-type="bibr" rid="ref-4">4</xref>,
<xref ref-type="bibr" rid="ref-49">49</xref>,
<xref ref-type="bibr" rid="ref-61">61</xref></sup>, heart
<sup><xref ref-type="bibr" rid="ref-62">62</xref>–
<xref ref-type="bibr" rid="ref-64">64</xref></sup>, and lung
<sup><xref ref-type="bibr" rid="ref-65">65</xref></sup>. This AAV-CRISPR-mediated gene editing in mice provided proof-of-principle studies for human disease modeling, gene therapy, or gene functional characterizations. We discuss recent developments and advancements in four critical aspects of the AAV-CRISPR system that have enabled efficient and precise
<italic>in vivo</italic> genome editing in mice.</p>
<table-wrap id="T2" orientation="portrait" position="anchor">
<label>Table 2. </label>
<caption>
<title>CRISPR/Cas9-based
<italic>in vivo</italic> genome editing in mice with tissue-specific promoters and AAV variants.</title>
</caption>
<table content-type="article-table" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Target tissue in
<break></break>mouse
<break></break>(disease or
<break></break>phenotype)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Promoter –
<break></break>regulates CRISPR or
<break></break>reporter</th>
<th align="left" colspan="1" rowspan="1" valign="top">AAV
<break></break>serotype</th>
<th align="left" colspan="1" rowspan="1" valign="top">Route of
<break></break>administration
<break></break>(injection site)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Application
<break></break>(gene)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Phenotypic impact or
<break></break>therapeutic outcome</th>
<th align="left" colspan="1" rowspan="1" valign="top">Remark</th>
<th align="left" colspan="1" rowspan="1" valign="top">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(study gene function)</td>
<td align="left" colspan="1" rowspan="1" valign="top">pMecp2 promoter - SpCas9
<break></break>hSyn1 promoter - GFP, KASH
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotactic injection
<break></break>(dentate gyrus)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>Mecp2</italic>,
<italic>Dnmt1</italic>,
<break></break>
<italic>Dnmt3a</italic>, and
<break></break>
<italic>Dnmt3b</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired contextual memory
<break></break>and memory formation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Can edit multiple
<break></break>genes simultaneously</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-25">25</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(study brain circuit)</td>
<td align="left" colspan="1" rowspan="1" valign="top">hSyn1 promoter - SaCas9,
<break></break>Cre recombinase, GCaMP6f
<break></break>calcium sensor
<break></break>CAG promoter - tdTomato
<break></break>U6 promoter - Grna</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV2-retro</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotactic injection
<break></break>(pontine nucleus,
<break></break>dorsal striatum)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>tdTomato</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Enabled efficient mapping,
<break></break>monitoring, and manipulation
<break></break>of projection neurons</td>
<td align="left" colspan="1" rowspan="1" valign="top">Modified AAV2
<break></break>capsid with a 7-mer
<break></break>peptide</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-68">68</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(Huntington disease)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SpCas9, eGFP
<break></break>U6 promoter - gRNA
<break></break>H1 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotactic injection
<break></break>(striata)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SNP-
<break></break>dependent
<break></break>editing (
<italic>Htt</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced expression of mutant
<break></break>
<italic>Htt</italic> allele in mouse brain</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use transgenic
<break></break>Huntington disease
<break></break>model</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-76">76</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(schizophrenia)</td>
<td align="left" colspan="1" rowspan="1" valign="top">EF1a promoter - tdTomato
<break></break>CBh promoter - ScGFP
<break></break>hSyn1 promoter - ScGFP
<break></break>GFAP promoter - ScGFP
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV2g9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotaxic injections
<break></break>(intracerebroventricular,
<break></break>cerebrospinal fluid)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene deletion
<break></break>(
<italic>pre-miR137</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Displayed preferential, robust,
<break></break>and widespread neuronal
<break></break>transduction within the brain</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use Cas9 mice and
<break></break>an AAV chimeric
<break></break>derived from AAV2
<break></break>and AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-80">80</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(inducible genome
<break></break>editing)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dox inducible Tight promoter
<break></break>- SpCas9
<break></break>TRE3G promoter - SpCas9
<break></break>pMecp2 - SpCas9
<break></break>CMV promoter - TetR, GFP,
<break></break>KASH
<break></break>H1/TO promoter - gRNA
<break></break>U6/TO promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV-DJ
<break></break>AAV-DJ/8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotaxic injection
<break></break>(basal and lateral
<break></break>amygdala)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene induction
<break></break>(
<italic>Tet2</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Edited the genomes of
<break></break>neurons
<italic>in vivo</italic> within the
<break></break>mouse brain in a Dox-
<break></break>dependent manner</td>
<td align="left" colspan="1" rowspan="1" valign="top">Doxycycline-
<break></break>dependent gRNA
<break></break>expression</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-81">81</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(study gene
<break></break>function)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CBh promoter - Cre
<break></break>recombinase
<break></break>hSyn1 promoter - GFP, KASH
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotactic injection
<break></break>(prefrontal cortex)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knock-in
<break></break>(
<italic>NeuN</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NeuN protein depletion only in
<break></break>the injected region</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use Cre-dependent
<break></break>SpCas9
<italic>Rosa26</italic>
<break></break>knock-in mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-65">65</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(glioblastoma)</td>
<td align="left" colspan="1" rowspan="1" valign="top">U6 promoter - gRNA
<break></break>GFAP promoter - Cre
<break></break>recombinase</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotactic injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene mutation
<break></break>(
<italic>Trp53</italic>,
<italic>Nf1</italic>, or
<break></break>
<italic>Rb1</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Induced tumor formation
<break></break>that recapitulates human
<break></break>glioblastoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use LSL-Cas9 mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-79">79</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(precise genome
<break></break>editing)</td>
<td align="left" colspan="1" rowspan="1" valign="top">EFS promoter - SpCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraventricular and
<break></break>stereotactic injections</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knock-in
<break></break>(
<italic>Camk2a</italic>,
<italic>Erk2</italic>,
<break></break>
<italic>Actb</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">vSLENDR enabled efficient
<break></break>homology-directed repair
<break></break>in post-mitotic neurons in
<break></break>developing, adult, aged, and
<break></break>pathological brains</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use wild-type and
<break></break>Cas9 mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-82">82</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brain
<break></break>(study gene function)</td>
<td align="left" colspan="1" rowspan="1" valign="top">U6 promoter - gRNA
<break></break>CBh promoter - Cre recombinase</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stereotactic injection
<break></break>(pyramidal neurons
<break></break>and microglia in
<break></break>hippocampus)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene
<break></break>disruption
<break></break>(
<italic>Cnr2</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased contextual fear
<break></break>memory, enhanced spatial
<break></break>working memory</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use Camk2a-Cas9,
<break></break>Gad2-Cas9, and
<break></break>Cx3cr1-Cas9 mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-83">83</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Central nervous
<break></break>system
<break></break>(amyotrophic lateral
<break></break>sclerosis)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SpCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">scAAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intrathecal injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene
<break></break>knockdown
<break></break>(
<italic>Igf1</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased D-amino acid
<break></break>oxidase and increased
<break></break>D-serine, and caspase9
<break></break>activation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use hSOD1G93A
<break></break>ALS mouse model</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-84">84</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Muscle
<break></break>(Duchenne muscular
<break></break>dystrophy)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SaCas9
<break></break>EFS promoter - SaCas9
<break></break>CAGGS promoter - tdTomato
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intramuscular
<break></break>(tibialis anterior)
<break></break>and intraperitoneal
<break></break>(intraperitoneal space)
<break></break>injections</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exon deletion
<break></break>(
<italic>Dmd</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Partially recovered muscle
<break></break>functional deficiencies</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use mdx mouse
<break></break>model of DMD</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-54">54</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Muscle
<break></break>(Duchenne muscular
<break></break>dystrophy)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intramuscular (tibialis
<break></break>anterior), intraperitoneal
<break></break>(intraperitoneal space),
<break></break>and intravenous (tail
<break></break>vein) injections</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exon deletion
<break></break>(
<italic>Dmd</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improved muscle function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use mdx mouse
<break></break>model of DMD</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-55">55</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Muscle
<break></break>(Duchenne muscular
<break></break>dystrophy)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SpCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal,
<break></break>intramuscular, and
<break></break>retro-orbital (venous
<break></break>sinus) injections</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exon deletion
<break></break>(
<italic>Dmd</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Enhanced skeletal muscle
<break></break>function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use mdx mouse
<break></break>model of DMD</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-56">56</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Muscle
<break></break>(Duchenne muscular
<break></break>dystrophy)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CK8 promoter - SpCas9,
<break></break>SaCas9
<break></break>CMV promoter - mCherry
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intramuscular (tibialis
<break></break>anterior) and systemic
<break></break>(retro-orbital) injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exon deletion
<break></break>and gene
<break></break>knock-in (
<italic>Dmd</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improved muscle function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use mdx4cv mouse
<break></break>model of DMD</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-57">57</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Muscle
<break></break>(congenital
<break></break>muscular dystrophy
<break></break>type 1A)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene
<break></break>correction
<break></break>(
<italic>Lama2</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improved muscle histopathology
<break></break>and function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use dy2J/dy2J mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-69">69</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retina
<break></break>(age-related macular
<break></break>degeneration)</td>
<td align="left" colspan="1" rowspan="1" valign="top">EFS promoter - CjCas9
<break></break>Spc512 promoter - CjCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intramuscular (tibialis
<break></break>anterior) and intravitreal
<break></break>injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>Rosa26</italic>,
<italic>Vegfa</italic>,
<break></break>and
<italic>Hif1a</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced the size of
<break></break>laser-induced choroidal
<break></break>neovascularization</td>
<td align="left" colspan="1" rowspan="1" valign="top">Smallest Cas9
<break></break>orthologue (smaller
<break></break>than SaCas9)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-5">5</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retina
<break></break>(Leber Congenital
<break></break>Amaurosis 10)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SpCas9,
<break></break>SaCas9
<break></break>hSyn1 promoter - eGFP
<break></break>GFAP promoter - eGFP
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Subretinal injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene deletion
<break></break>(
<italic>Cep290</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Effectively removed intronic
<break></break>mutation in
<italic>Cep290</italic> with
<break></break>minimized immune response</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use self-limiting
<break></break>CRISPR/Cas9 system</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-58">58</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retina
<break></break>(retinal gene editing)</td>
<td align="left" colspan="1" rowspan="1" valign="top">pMecp2 promoter - SpCas9
<break></break>hSyn1 promoter - mCherry,
<break></break>KASH
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intravitreal (intraocular)
<break></break>injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>YFP</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Effective gene knockout without
<break></break>affecting retinal function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use Thy1-YFP
<break></break>transgenic mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-59">59</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retina
<break></break>(retinal degeneration)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SpCas9,
<break></break>tdTomato
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Subretinal injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>Nrl</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prevented retinal degeneration,
<break></break>improved rod survival, and
<break></break>preserved cone function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use mouse models of
<break></break>retinal degeneration</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-60">60</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Retina
<break></break>(angiogenesis)</td>
<td align="left" colspan="1" rowspan="1" valign="top">pICAM2 - SpCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intravitreal injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene silencing
<break></break>(
<italic>VEGFR2</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Abrogated angiogenesis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use mouse models
<break></break>of oxygen-induced
<break></break>retinopathy and
<break></break>laser-induced choroid
<break></break>neovascularization</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-85">85</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liver
<break></break>(ornithine
<break></break>transcarbamylase)</td>
<td align="left" colspan="1" rowspan="1" valign="top">TBG promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intravenous injection
<break></break>(temporal vein)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knock-in
<break></break>(
<italic>Otc</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased survival in mice
<break></break>challenged with a high-protein
<break></break>diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use adult OTC-
<break></break>deficient mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-49">49</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liver
<break></break>(hereditary
<break></break>tyrosinemia)</td>
<td align="left" colspan="1" rowspan="1" valign="top">EF1a promoter - GFP
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systemic (tail vein)
<break></break>injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knock-in
<break></break>(
<italic>Fah</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rescued disease symptoms
<break></break>such as weight loss and liver
<break></break>damage</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use a mouse model
<break></break>of human hereditary
<break></break>tyrosinemia</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-61">61</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liver
<break></break>(total cholesterol)</td>
<td align="left" colspan="1" rowspan="1" valign="top">TBG promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systemic (tail vein)
<break></break>injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>Pcsk9</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced serum Pcsk9 and
<break></break>total cholesterol levels</td>
<td align="left" colspan="1" rowspan="1" valign="top">Smaller Cas9
<break></break>orthologue than
<break></break>SpCas9</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-4">4</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liver
<break></break>(LDL cholesterol)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CB promoter - EmGFP
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>Ldlr</italic>,
<italic>Apob</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Resulted in severe
<break></break>hypercholesterolemia and
<break></break>atherosclerosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use Cas9 targeted
<break></break>transgenic mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-77">77</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liver
<break></break>(hemophilia B)</td>
<td align="left" colspan="1" rowspan="1" valign="top">HCRhAATp promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systemic (tail vein)
<break></break>injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knock-in
<break></break>(
<italic>F9</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Restored hemostasis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use
<italic>F9</italic>-mutated mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-71">71</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Heart
<break></break>(PRKAG2 cardiac
<break></break>syndrome)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SpCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systemic injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>Prkag2</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Restored the morphology
<break></break>and function of the heart after
<break></break>disrupting the mutant
<italic>Prkag2</italic>
<break></break>allele</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use H530R
<italic>Prkag2</italic>
<break></break>transgenic knock-in
<break></break>mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-62">62</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Heart
<break></break>(cardiac disease
<break></break>modeling)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myh6 promoter - SpCas9, GFP,
<break></break>TdTomato
<break></break>CMV promoter - ZsGreen
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene deletion
<break></break>(
<italic>Myh6</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Displayed severe
<break></break>cardiomyopathy and loss of
<break></break>cardiac function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use postnatal
<break></break>cardiac-Cas9
<break></break>transgenic mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-63">63</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Heart
<break></break>(cardiac myocyte
<break></break>maturation)</td>
<td align="left" colspan="1" rowspan="1" valign="top">cTNT promoter - Cre
<break></break>recombinase
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Subcutaneous injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(
<italic>Jph2</italic>,
<italic>Ryr2</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disrupted T-tubule structure
<break></break>and maturation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use RosaCas9GFP/
<break></break>Cas9GFP neonatal
<break></break>mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-78">78</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Heart
<break></break>(dystrophic
<break></break>cardiomyopathy)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CK7-miniCMV promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV rh74</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systemic (retro-orbital,
<break></break>intraperitoneal) injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene excision
<break></break>(
<italic>Dmd</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Restored dystrophin expression
<break></break>and cardiac function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use mdx/Utr
<sup>+</sup>/
<sup>−</sup>
<break></break>dystrophic mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-70">70</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Heart
<break></break>(cardiac gene
<break></break>function)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CB promoter - SpCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intracardiac</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene disruption
<break></break>(
<italic>Myh6</italic>,
<italic>Sav1</italic>,
<break></break>and
<italic>Tbx20</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Resulted in mosaic pattern of
<break></break>gene disruption</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use Myh6-Cre
<break></break>transgenic mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-64">64</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lung
<break></break>(lung
<break></break>adenocarcinoma)</td>
<td align="left" colspan="1" rowspan="1" valign="top">EFS promoter - Renilla
<break></break>luciferase, Cre recombinase
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intranasal (nostril) and
<break></break>intratracheal (trachea)
<break></break>injections</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knock-in
<break></break>(
<italic>p53</italic>,
<italic>Lkb1</italic>,
<break></break>and
<italic>Kras</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Led to macroscopic tumors
<break></break>of lung adenocarcinoma
<break></break>pathology</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use Cre-dependent
<break></break>SpCas9
<italic>Rosa26</italic>
<break></break>knock-in mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-65">65</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liver, heart, muscle
<break></break>(host immune
<break></break>response)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SMVP promoter - SpCas9,
<break></break>SpCas9-VPR
<break></break>CASI promoter - SpCas9
<break></break>CAG promoter - tdTomato
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intramuscular and
<break></break>intraperitoneal
<break></break>injections</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene
<break></break>activation
<break></break>(
<italic>Mstn</italic>,
<italic>Fst</italic>,
<italic>Pd-l1</italic>,
<break></break>and
<italic>Cd47</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Modest activation of
<italic>Pd-l1</italic> and
<break></break>
<italic>Cd47</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use AAV-split-Cas9
<break></break>system</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-50">50</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Circulating
<break></break>lymphocytes, spleen,
<break></break>liver, heart, lung,
<break></break>and kidney
<break></break>(eradication of HIV-1
<break></break>DNA)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systemic (tail vein)
<break></break>injection and retro-
<break></break>orbital inoculation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene knockout
<break></break>(HIV-1 DNA)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Eradication of HIV-1 DNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use transgenic
<break></break>mice and rats
<break></break>encompassing the
<break></break>HIV-1 genome</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-86">86</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Spleen, lungs, heart,
<break></break>colon, and brain
<break></break>(HIV-1 proviral DNA
<break></break>excision)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CMV promoter - SaCas9
<break></break>U6 promoter - gRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">AAV-DJ/8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Systemic (tail vein)
<break></break>injection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gene deletion
<break></break>(HIV-1 DNA)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Induced efficient excision of
<break></break>HIV-1 proviral DNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Use HIV-1 Tg26
<break></break>transgenic mice and
<break></break>humanized BLT mice
<break></break>with chronic HIV-1
<break></break>infection</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="ref-72">72</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AAV, adeno-associated virus; ALS, amyotrophic lateral sclerosis;
<italic>Apob</italic>, apolipoprotein B; BLT, bone marrow/liver/thymus; CAG, a hybrid of CMV early enhancer and chicken beta-actin promoter; CAGGS, a hybrid of promoter composed of the CMV immediate-early enhancer, CBA promoter, and CBA intron 1/exon 1;
<italic>Camk2a</italic>, calcium/calmodulin-dependent protein kinase II alpha; CASI, a hybrid of CMV enhancer and chicken β-actin promoter followed by a splice donor and splice acceptor; CB, chicken beta actin promoter; CBh, a hybrid form of the CBA promoter;
<italic>Cd47</italic>, integrin-associated signal transducer;
<italic>Cep290</italic>, centrosomal protein 290; CjCas9,
<italic>Campylobacter jejuni</italic> Cas9; CK7, CK8, striated muscle-restricted promoter; CMV, cytomegalovirus;
<italic>Cnr2</italic>, cannabinoid receptor 2; CRISPR, clustered regularly interspaced short palindromic repeat; cTNT, cardiac troponin T promoter;
<italic>Cx3cr1</italic>, chemokine (C-X3-C motif) receptor 1;
<italic>Dmd</italic>, Duchenne muscular dystrophy;
<italic>Dnmt</italic>, DNA methyltransferase; EF1a, elongation factor-1 alpha; EFS, EF1a short; eGFP, enhanced green fluorescent protein;
<italic>Erk2</italic>, mitogen-activated protein kinase 1;
<italic>F9</italic>, coagulation factor IX;
<italic>Fah</italic>, fumarylacetoacetate hydrolase;
<italic>Fst</italic>, follistatin;
<italic>Gad2</italic>, glutamic acid decarboxylase 2; GCaMP6f, green fluorescent calcium indicator; GFAP, glial fibrillary acidic protein; H1, human polymerase III RNA promoter; HCRhAATp, an enhancer element of the hepatic control region of the Apo E/C1 gene and the human anti-trypsin promoter;
<italic>Hif1a</italic>, hypoxia-inducible factor 1 alpha; HIV, human immunodeficiency virus; hSyn1, human synapsin I;
<italic>Htt</italic>, huntingtin;
<italic>Igf1</italic>, insulin-like growth factor 1;
<italic>Jph2</italic>, junctophilin-2; KASH, nuclear transmembrane domain;
<italic>Kras</italic>, Kirsten rat sarcoma viral oncogene homolog;
<italic>Lama2</italic>, laminin alpha 2; LDL, low-density lipoprotein;
<italic>Ldlr</italic>, low-density lipoprotein receptor;
<italic>Lkb1</italic>, serine/threonine kinase 11; mdx, dystrophin-deficient;
<italic>Mecp2</italic>, methyl CpG binding protein 2;
<italic>Mstn</italic>, myostatin;
<italic>Myh6</italic>, myosin heavy polypeptide 6;
<italic>NeuN</italic>, neuronal nuclear antigen;
<italic>Nf1</italic>, neurofibromin 1;
<italic>Nrl</italic>, neural retina-specific leucine zipper protein;
<italic>Otc</italic>, ornithine transcarbamylase;
<italic>Pcsk9</italic>, proprotein convertase subtilisin/kexin type 9;
<italic>Pd-l1</italic>, programmed death-ligand 1; pICAM2, intercellular adhesion molecule 2 promoter;
<italic>Prkag2</italic>, protein kinase AMP-activated non-catalytic subunit gamma 2;
<italic>p53</italic>, transformation related protein 53;
<italic>Rb1</italic>, RB transcriptional corepressor 1;
<italic>Roa26</italic>, a safe harbor locus in mouse;
<italic>Ryr2</italic>, ryanodine receptor 2; SaCas9,
<italic>Staphylococcus aureus</italic> Cas9;
<italic>Sav1</italic>, salvador family WW domain containing 1; SMVP, a hybrid of SV40 enhancer–CMV–promoter–chimeric intron; SNP, single-nucleotide polymorphism; SpCas9,
<italic>Streptococcus pyogenes</italic> Cas9; Spc512, muscle-specific promoter; TBG, thyroxine binding globulin;
<italic>Tbx20</italic>, T-box 20;
<italic>Tet2</italic>, tet methylcytosine dioxygenase 2;
<italic>Thy1</italic>, thymus cell antigen 1 theta; TRE3G, Tet-On 3G inducible promoter; TO, tetracycline operator; U6, human U6 small nuclear promoter;
<italic>Vegfa</italic>, vascular endothelial growth factor A;
<italic>VEGFR2</italic>, kinase insert domain protein receptor; VPR, a fusion of VP64–p65–Rta; vSLENDR, virus-mediated single-cell labeling of endogenous proteins via HDR; YFP, yellow fluorescent protein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec>
<title>Small Cas9 orthologues</title>
<p>Even though the AAV vector is an extremely attractive delivery vehicle for CRISPR, its relatively small viral genome-packaging capacity has limited its use for delivering large transgenes. Using dual-vector AAV system or smaller Cas9 orthologues along with truncated regulatory elements (promoter and polyadenylation signal) has greatly circumvented the transgene packaging issue (
<xref ref-type="fig" rid="f1">Figure 1A</xref>). Owing to a small AAV viral genome-packaging capacity (~4.8 kb), it has been technically challenging to co-package
<italic>Streptococcus pyogenes</italic>-derived Cas9 (SpCas9) (4.1 kb) and multiple sgRNAs into all-in-one AAV vectors for multiplex genome editing. Recently, it has been demonstrated that when very small promoters were used (for example, miCMV promoter and H1 promoter to drive the expressions of SpCas9 and its gRNA, respectively), it was possible to package both SpCas9 and its gRNA into a single vector
<sup><xref ref-type="bibr" rid="ref-32">32</xref></sup>. However, the number of promoters that can be selected for tissue-specific transduction is limited. To circumvent this issue, the previously reported dual-vector system was adopted to express SpCas9 nuclease from one vector and to express its gRNAs together with a fluorescent reporter gene from another vector
<sup><xref ref-type="bibr" rid="ref-25">25</xref></sup>. Recently, St1Cas9 (~3.3 kb) from
<italic>Streptococcus thermophilus</italic>
<sup><xref ref-type="bibr" rid="ref-66">66</xref></sup> and a rationally designed truncated form of SpCas9
<sup><xref ref-type="bibr" rid="ref-67">67</xref></sup> were developed to fit SpCas9 and its gRNA into a single AAV construct. Unfortunately, St1Cas9 requires a more complex PAM sequence that limits the number of targetable loci
<sup><xref ref-type="bibr" rid="ref-66">66</xref></sup>, and truncated SpCas9 has a much lower efficiency than its wild-type counterpart
<sup><xref ref-type="bibr" rid="ref-67">67</xref></sup>.</p>
<fig fig-type="figure" id="f1" orientation="portrait" position="anchor">
<label>Figure 1. </label>
<caption>
<title>CRISPR/Cas9-based
<italic>in vivo</italic> genome editing by using small Cas9 orthologues, different routes of AAV administration, tissue-specific minimal promoters, and AAV serotypes.</title>
<p>(
<bold>A</bold>) AAV-CRISPR vectors.
<italic>Campylobacter jejuni</italic>-derived Cas9 (CjCas9) is the smallest Cas9 orthologue (984 amino acids, 2.95 kb).
<italic>Staphylococcus aureus</italic>-derived Cas9 (SaCas9) (1,053 amino acids, 3.16 kb) is smaller than the most widely used Cas9 derived from
<italic>Streptococcus pyogenes</italic> (SpCas9) (1,368 amino acids, 4.10 kb). Owing to the large size of SpCas9, the SpCas9 gene and two gRNAs are packaged into two separate AAV vectors. The SpCas9-based dual-vector system enables one vector to express SpCas9 and another to express multiple gRNAs and a fluorescent reporter gene. Two gRNAs can be packaged with the SaCas9 into a single AAV vector if minimal promoter and polyadenylation signal are used. In the all-in-one vector system, CjCas9 enables packaging with two gRNAs and a fluorescent reporter gene, enhanced green fluorescent protein (
<italic>eGFP</italic>), into a single AAV vector. (
<bold>B</bold>) AAV serotypes for tissue-targeted delivery. (
<bold>C</bold>) Tissue-specific minimal promoters for driving CRISPR expression. (
<bold>D</bold>) Different routes of AAV administration into various tissues of a mouse. AAV, adeno-associated virus; CRISPR, clustered regulatory interspaced short palindromic repeat; gRNA, guide RNA.</p>
</caption>
<graphic xlink:href="f1000research-6-12130-g0000"></graphic>
</fig>
<p>To overcome these drawbacks, other recently discovered small Cas9 orthologues, including
<italic>Staphylococcus aureus</italic>-derived Cas9 (SaCas9, 3.16 kb)
<sup><xref ref-type="bibr" rid="ref-4">4</xref></sup> and
<italic>Campylobacter jejuni</italic>-derived Cas9 (CjCas9, 2.95 kb)
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>, have been used to package the Cas9 and its gRNA into a single AAV delivery vehicle for
<italic>in vivo</italic> genome editing. To date, at least 11 independent
<italic>in vivo</italic> studies have used the AAV-SaCas9 system to edit disease-associated genes in a variety of tissues, including brain
<sup><xref ref-type="bibr" rid="ref-68">68</xref></sup>, muscle
<sup><xref ref-type="bibr" rid="ref-54">54</xref>,
<xref ref-type="bibr" rid="ref-55">55</xref>,
<xref ref-type="bibr" rid="ref-57">57</xref>,
<xref ref-type="bibr" rid="ref-69">69</xref></sup>, retina
<sup><xref ref-type="bibr" rid="ref-58">58</xref></sup>, heart
<sup><xref ref-type="bibr" rid="ref-70">70</xref></sup>, and liver
<sup><xref ref-type="bibr" rid="ref-4">4</xref>,
<xref ref-type="bibr" rid="ref-49">49</xref>,
<xref ref-type="bibr" rid="ref-71">71</xref></sup>. More recently, the quadruplex gRNAs/SaCas9 vector consisting of SaCas9 and multiplex sgRNAs was successfully delivered using AAV-DJ/8 for
<italic>in vivo</italic> excision of HIV-1 proviral DNA in various solid tissues/organs via a single intravenous injection in humanized bone marrow/liver/thymus (BLT) mice with chronic HIV-1 infection
<sup><xref ref-type="bibr" rid="ref-72">72</xref></sup>. In the all-in-one vector system, CjCas9 can be packaged with multiple gRNAs and even a fluorescent reporter gene into a single AAV vector
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>. Even though CjCas9 represents the smallest Cas9 orthologue characterized to date, only one
<italic>in vivo</italic> study has demonstrated the use of AAV vectors to deliver CjCas9 into the mouse’s retina for the treatment of age-related macular degeneration because of the recent development of CjCas9
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>. Excitingly, AAV-CjCas9 offers the possibility of editing multiplex genes and tracking the expression of fluorescent reporter genes at high efficiency by simply introducing a single type of AAV vector into the mouse body. The CRISPR-mediated genome-editing specificities can be further improved by adopting truncated gRNAs
<sup><xref ref-type="bibr" rid="ref-73">73</xref></sup> and small chemical molecules to regulate Cas9 activity
<sup><xref ref-type="bibr" rid="ref-74">74</xref></sup> or to enhance double-stranded break-induced homologous recombination efficiency
<sup><xref ref-type="bibr" rid="ref-75">75</xref></sup> without sacrificing on-target genome-editing efficiencies.</p>
</sec>
<sec>
<title>Natural and engineered AAV serotypes</title>
<p>Multiple naturally occurring AAV serotypes have been harnessed to deliver the CRISPR/Cas9 complex into different tissues and organs in mice (
<xref ref-type="fig" rid="f1">Figure 1B</xref>). AAV1 is particularly efficient to drive CRISPR transgene expression in the brain
<sup><xref ref-type="bibr" rid="ref-25">25</xref>,
<xref ref-type="bibr" rid="ref-65">65</xref>,
<xref ref-type="bibr" rid="ref-76">76</xref></sup>, whereas AAV8 appears well suited for the transduction of liver
<sup><xref ref-type="bibr" rid="ref-4">4</xref>,
<xref ref-type="bibr" rid="ref-49">49</xref>,
<xref ref-type="bibr" rid="ref-61">61</xref>,
<xref ref-type="bibr" rid="ref-71">71</xref>,
<xref ref-type="bibr" rid="ref-77">77</xref></sup> and muscle
<sup><xref ref-type="bibr" rid="ref-55">55</xref></sup> in mice. AAV9 has the general ability to transduce all major tissues, including muscle
<sup><xref ref-type="bibr" rid="ref-54">54</xref>,
<xref ref-type="bibr" rid="ref-56">56</xref>,
<xref ref-type="bibr" rid="ref-69">69</xref></sup>, retina
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>, heart
<sup><xref ref-type="bibr" rid="ref-62">62</xref>–
<xref ref-type="bibr" rid="ref-64">64</xref>,
<xref ref-type="bibr" rid="ref-78">78</xref></sup>, and lung
<sup><xref ref-type="bibr" rid="ref-65">65</xref></sup>, in mice. Recently, the AAV9-CRISPR system has been successfully used to identify functional tumor suppressors in glioblastoma by performing high-throughput mutagenesis in the brain of conditional-Cas9 mice to recapitulate human glioblastoma
<sup><xref ref-type="bibr" rid="ref-79">79</xref></sup>. AAV2
<sup><xref ref-type="bibr" rid="ref-59">59</xref></sup> and AAV5
<sup><xref ref-type="bibr" rid="ref-58">58</xref></sup> have also been used to transduce retina, whereas AAV6
<sup><xref ref-type="bibr" rid="ref-57">57</xref></sup> enables CRISPR-mediated gene editing in muscle tissue.</p>
<p>In order to alter tropism, reduce blockage by neutralizing antibodies, or enhance transduction efficiency, AAV capsids have been chemically or genetically modified to produce hybrid capsids by combining the properties of multiple serotypes, capsid shuffling, directed evolution, rational mutagenesis, or carrying peptide insertions that introduce the novel receptor-binding activity. AAV variants with engineered capsids (AAV2-retro, AAV2g9, AAV-DJ, and AAV-DJ/8) have been used to package CRISPR for transduction in the mouse brain. An
<italic>in vivo</italic>-directed evolution-engineered AAV variant, rAAV2-retro, permits robust retrograde access to projection neurons in functionally connected and highly distributed networks with a high efficiency for neural circuit dissection and
<italic>in vivo</italic> genome editing
<sup><xref ref-type="bibr" rid="ref-68">68</xref></sup>. An AAV chimera derived from AAV2 and AAV9, AAV2g9, enables preferential, robust, and widespread neuronal transduction within the mouse brain for CRISPR/Cas9-mediated gene deletion for the treatment of neurological disorders
<sup><xref ref-type="bibr" rid="ref-80">80</xref></sup>. To provide substantially higher infectivity rates across a broad range of tissues than any known native serotypes, the AAV-DJ was engineered by DNA family shuffling to create a hybrid capsid from eight different native serotypes
<sup><xref ref-type="bibr" rid="ref-87">87</xref></sup>. AAV-DJ/8 was created by introducing two point mutations in the heparin-binding domain of AAV-DJ to increase uptake in brain tissue
<italic>in vivo</italic>, leading to a similar ability to infect heart and brain tissues with AAV8 and AAV9
<sup><xref ref-type="bibr" rid="ref-87">87</xref>,
<xref ref-type="bibr" rid="ref-88">88</xref></sup>. In fact, AAV-DJ/8 has been successfully used alongside the CRISPR/Cas9 system with doxycycline-dependent gRNA expression for inducible genome editing of neurons
<italic>in vivo</italic> within the mouse brain
<sup><xref ref-type="bibr" rid="ref-81">81</xref></sup>. AAV-DJ/8 has also been successfully used to package and deliver the CRISPR/SaCas9 vectors for
<italic>in vivo</italic> excision of HIV-1 proviral DNA in animal models
<sup><xref ref-type="bibr" rid="ref-72">72</xref></sup>.</p>
<p>Recently, the capsids of AAV9, which is the most efficient native serotype characterized to date for
<italic>in vivo</italic> transduction of the brain, have been further engineered for better performance in transductions and tissue targeting specificity. These include AAV-PHP.B (a chimeric AAV9 variant generated by inserting a 7-mer sequence, TLAVPFK, on AAV9 capsid)
<sup><xref ref-type="bibr" rid="ref-13">13</xref></sup>, AAV-AS (a chimeric AAV9 variant generated by inserting a poly-alanine peptide on AAV9 capsid)
<sup><xref ref-type="bibr" rid="ref-14">14</xref></sup>, and AAV9/3 (double tyrosine-mutant form of AAV9)
<sup><xref ref-type="bibr" rid="ref-89">89</xref></sup>, all of which were shown to be more efficient in transductions of the adult mouse central nervous system after intravenous injection compared with the wild-type AAV9. Furthermore, some of these engineered AAV capsids could de-target the native AAV tropism without affecting vector production, capsid assembly, infectivity, and gene transfer. Therefore, these novel engineered vectors offer promising options to package the CRISPR/Cas9 complex to efficiently edit disease-associated genes in the mouse brain or any other tissues. Additionally, self-complementary AAV9 (scAAV9) can be used to significantly decrease the time required for the onset of CRISPR expression in the central nervous system of mice
<sup><xref ref-type="bibr" rid="ref-84">84</xref></sup>. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant AAV vectors
<sup><xref ref-type="bibr" rid="ref-31">31</xref></sup>. The use of double-stranded self-complementary AAV (scAAV) has improved the transduction efficiencies by bypassing the second-strand synthesis step, but cloning capacity was further reduced to accommodate the complementary strand
<sup><xref ref-type="bibr" rid="ref-90">90</xref></sup>.</p>
</sec>
<sec>
<title>Tissue-specific minimal promoters</title>
<p>A tissue-specific promoter is important to ensure the expression of the CRISPR transgene in a tissue- or organ-specific manner. Various truncated or minimal tissue-specific promoters have been used to drive the expression of CRISPR in specific tissues upon injection of the AAV vectors into the mouse body (
<xref ref-type="fig" rid="f1">Figure 1C</xref>). For example, the 235 base pair (bp) mouse pMecp2 (methyl CpG binding protein 2) and 485 bp human hSyn1 (human synapsin I) promoters have been used to efficiently and specifically drive the expression of CRISPR and other transgenes in the mouse brain
<sup><xref ref-type="bibr" rid="ref-25">25</xref></sup> and retina
<sup><xref ref-type="bibr" rid="ref-59">59</xref></sup>. A striated muscle-restricted promoter, CK8, enabled specific expression of SpCas9 and SaCas9 for gene editing in the muscle of the mdx mouse model of Duchenne muscular dystrophy upon intramuscular (tibialis anterior) or systemic (retro-orbital) injection of AAV6 vectors
<sup><xref ref-type="bibr" rid="ref-57">57</xref></sup>. The liver-specific TBG (thyroxine binding globulin)
<sup><xref ref-type="bibr" rid="ref-4">4</xref>,
<xref ref-type="bibr" rid="ref-49">49</xref></sup> and cardiac-specific Myh6 (myosin heavy polypeptide 6)
<sup><xref ref-type="bibr" rid="ref-63">63</xref></sup> promoters have been successfully used to drive the expression of CRISPR for
<italic>in vivo</italic> genome editing in mouse liver and heart, respectively. More general promoters such as CMV (cytomegalovirus)
<sup><xref ref-type="bibr" rid="ref-54">54</xref>,
<xref ref-type="bibr" rid="ref-58">58</xref>,
<xref ref-type="bibr" rid="ref-60">60</xref>,
<xref ref-type="bibr" rid="ref-62">62</xref></sup> and EFS (elongation factor-1 alpha short)
<sup><xref ref-type="bibr" rid="ref-5">5</xref>,
<xref ref-type="bibr" rid="ref-65">65</xref></sup> can be used to express the CRISPR in multiple tissues, including muscle, retina, heart, and lung, for simultaneous gene editing of various tissues in mice. Compared with the CMV promoter, the elongation factor-1 alpha (EF1a) promoter tends to give more consistent and prolonged expression regardless of cell type or physiology
<sup><xref ref-type="bibr" rid="ref-91">91</xref>,
<xref ref-type="bibr" rid="ref-92">92</xref></sup>. EF1a is more stable in long-term culture because it maintains high transgene expression and stability and the copy number of episomal vectors
<sup><xref ref-type="bibr" rid="ref-91">91</xref></sup>. Thus, despite a stronger gene expression driven by the CMV promoter in many mammalian cell types, EF1a is preferred for efficient transgene expression in mouse embryonic stem cell lines
<sup><xref ref-type="bibr" rid="ref-93">93</xref></sup> and for engineering stable tumor cell lines
<sup><xref ref-type="bibr" rid="ref-92">92</xref></sup>. The library of minimal tissue-specific promoters alongside AAV vectors used for controlling the expression of CRISPR or other transgenes
<italic>in vivo</italic> is expanding with the development of more tightly regulated synthetic hybrid promoters, such as widely used CAG, CAGGS, CASI, CBh, GFAP, TRE3G, SMVP, Spc512, H1/T0, CK7-miniCMV, pICAM2, HCRhAATp, and Tight promoters (
<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<p>Chimeric gRNA expression is frequently driven by an RNA polymerase III promoter, most often by the human U6 small nuclear (U6) promoter. The human U6 promoter has been shown to be more efficient than its murine homolog for short hairpin RNA (shRNA) expression in both human and murine cells
<sup><xref ref-type="bibr" rid="ref-94">94</xref></sup>. The human U6 promoter was also proven more efficient than the human H1 promoter in driving shRNA expression for the long-term inhibition of gene expression
<italic>in vitro</italic> and
<italic>in vivo</italic>
<sup><xref ref-type="bibr" rid="ref-95">95</xref></sup>. However, the use of the U6 promoter to overexpress shRNAs
<italic>in vivo</italic> can induce severe hepatotoxicity and inflammatory side effects due to abundant shRNA production
<sup><xref ref-type="bibr" rid="ref-96">96</xref></sup>. The weaker H1 promoter may offer a safer option in this case, but its therapeutic efficacy is dependent on the sequence of the shRNA
<sup><xref ref-type="bibr" rid="ref-96">96</xref></sup>. Some promoters require a particular nucleotide as the transcription start site (TSS) to initiate transcription. For instance, the human or mouse U6 promoters require a guanine nucleotide (G) at the 5′ end of the transcript for effective transcription
<sup><xref ref-type="bibr" rid="ref-97">97</xref></sup>. To use the U6 promoter for driving gRNA expression, the first nucleotide of the transcribed gRNA should be a G to maximize U6 promoter activity
<sup><xref ref-type="bibr" rid="ref-97">97</xref></sup>. If the G is absent at the TSS of the gRNA sequence, the human RNA polymerase III promoter H1 can be used to drive the expression of the gRNA
<sup><xref ref-type="bibr" rid="ref-76">76</xref></sup>. The use of H1 promoter-expressed gRNAs could enhance the versatility of the CRISPR technology by expanding the targetable genome
<sup><xref ref-type="bibr" rid="ref-98">98</xref></sup>. For multiplex CRISPR/Cas9-based genome editing such as large genomic DNA deletion or synergistically enhanced gene activation and repression, four independent polymerase III promoters (human U6 promoter, murine U6 promoter, 7SK, and H1) can be used to express four gRNAs in a single expression cassette
<sup><xref ref-type="bibr" rid="ref-21">21</xref></sup>. The use of distinct polymerase III promoters can avoid the problem of genetic recombination in a viral vector and the loss of the proximal gRNA due to identical DNA sequences of the promoters
<sup><xref ref-type="bibr" rid="ref-99">99</xref></sup>. The doxycycline-dependent promoters such as H1/TO and U6/TO can also be used for inducible
<italic>in vivo</italic> genome editing by supplying animals with Dox-containing food to regulate the expression of the gRNA in a Dox-dependent manner
<sup><xref ref-type="bibr" rid="ref-81">81</xref></sup>. The introduction of Dox inhibits Tet repressor (TetR) binding and induces gRNA expression
<sup><xref ref-type="bibr" rid="ref-81">81</xref></sup>.</p>
</sec>
<sec>
<title>Local and global delivery of AAV vectors</title>
<p>The route of administration of AAV-CRISPR vectors into the mouse body also determines the efficacy and specificity of gene editing for
<italic>in vivo</italic> therapeutics (
<xref ref-type="fig" rid="f1">Figure 1D</xref>). Given the inability of the most native AAV serotypes (except for AAV9
<sup><xref ref-type="bibr" rid="ref-100">100</xref></sup>, AAVrh8
<sup><xref ref-type="bibr" rid="ref-101">101</xref></sup>, and AAVrh10
<sup><xref ref-type="bibr" rid="ref-102">102</xref></sup>) to cross the blood-brain barrier, stereotactic
<sup><xref ref-type="bibr" rid="ref-25">25</xref>,
<xref ref-type="bibr" rid="ref-65">65</xref>,
<xref ref-type="bibr" rid="ref-76">76</xref></sup> and intrathecal
<sup><xref ref-type="bibr" rid="ref-84">84</xref></sup> injections are still the preferred routes to systemic injection in order to introduce the AAV-CRISPR vectors into specific regions of the mouse brain or central nervous system for therapeutic gene editing. For the stereotactic injection, AAV-CRISPR vectors are intracranially injected into the brain by using a stereotaxic apparatus and the injection micropipette. In the intrathecal injection approach, AAV-CRISPR vectors are injected into the spinal canal or subarachnoid space to reach cerebrospinal fluid. For efficient therapeutic gene editing in the mouse muscle tissue, intramuscular (via tibialis anterior), intraperitoneal (via intraperitoneal space), or intravenous (via the tail vein, temporal vein, and retro-orbital) injections are the preferred methods to introduce AAV-CRISPR vectors, as have been demonstrated for the mdx mouse model of Duchenne muscular dystrophy
<sup><xref ref-type="bibr" rid="ref-55">55</xref>–
<xref ref-type="bibr" rid="ref-57">57</xref></sup>. Subretinal
<sup><xref ref-type="bibr" rid="ref-58">58</xref>,
<xref ref-type="bibr" rid="ref-60">60</xref></sup> or intravitreal
<sup><xref ref-type="bibr" rid="ref-59">59</xref>,
<xref ref-type="bibr" rid="ref-85">85</xref></sup> injections are used to deliver AAV-CRISPR vectors into the mouse retina for gene editing. As most of the AAV vectors will accumulate in the mouse liver tissue upon systemic injection, intravenous injection by tail vein or temporal vein can efficiently edit the genes associated with liver diseases
<sup><xref ref-type="bibr" rid="ref-4">4</xref>,
<xref ref-type="bibr" rid="ref-49">49</xref>,
<xref ref-type="bibr" rid="ref-71">71</xref></sup>. Systemic injection remains preferred to local injection in the liver tissue because the delivery is more uniform and the distribution of viral vectors is broader. It is also a good delivery mode for gene editing in multiple tissues, as it is almost non-invasive to the body. On the other hand, intracardiac
<sup><xref ref-type="bibr" rid="ref-64">64</xref></sup>, subcutaneous
<sup><xref ref-type="bibr" rid="ref-78">78</xref></sup>, intraperitoneal
<sup><xref ref-type="bibr" rid="ref-63">63</xref></sup>, or systemic
<sup><xref ref-type="bibr" rid="ref-62">62</xref>,
<xref ref-type="bibr" rid="ref-70">70</xref></sup> injection has been used to introduce AAV9 vectors carrying CRISPR transgene into the mouse heart for gene editing. Intranasal and intratracheal injections are used to locally deliver the AAV-CRISPR vehicles into the mouse lung tissue
<sup><xref ref-type="bibr" rid="ref-65">65</xref></sup>. Therefore, the selection of an effective route of injections is dependent on the target tissue, AAV serotypes, and tissue-specific promoters used.</p>
</sec>
</sec>
<sec>
<title>CRISPR/Cas9-based human gene and cell therapies</title>
<p>In August 2016, the first human clinical trial using a CRISPR-based gene-editing technique was started for cancer immunotherapy of metastatic non-small cell lung cancer
<sup><xref ref-type="bibr" rid="ref-103">103</xref></sup>. Subsequently, 10 more early phase clinical trials are underway (ClinicalTrials.gov). One of these clinical trials has proceeded to phase 2 for the treatment of advanced esophageal cancer. Six of these early phase clinical trials are using the CRISPR/Cas9 system to create genetically altered immune cells, which are infused back into patients with an advanced stage of lung, bladder, prostate, renal, gastric, esophageal, or nasopharyngeal carcinoma or lymphoma to target and eradicate cancer cells (
<xref ref-type="table" rid="T3">Table 3</xref>). In general, the programmed cell death protein 1 gene (
<italic>PDCD1</italic>) will be knocked out in autologous T cells. These engineered T cells then will be selected and expanded
<italic>ex vivo</italic> before infusion back into the patients. PDCD1, more commonly known as PD-1, is an inhibitory cell surface receptor involved in the regulation of T-cell function during immune response and tolerance. Knockout of
<italic>PD-1</italic> in T cells extracted from the patient’s blood could prevent cells’ immune response from switch-off after re-introduction of the gene-edited cells into the patient’s bloodstream and attack and defeat the cancer cells
<sup><xref ref-type="bibr" rid="ref-104">104</xref></sup>. In fact, antibodies (for example, nivolumab and pembrolizumab) that neutralize PD-1 with high response and low adverse effect rates have been successfully used for cancer immunotherapy in human clinical trials
<sup><xref ref-type="bibr" rid="ref-105">105</xref>,
<xref ref-type="bibr" rid="ref-106">106</xref></sup>. Gene editing is expected to inhibit PD-1 with a greater certainty, and by multiplying the cells in the laboratory, scientists can enhance the efficacy of triggering an immune response against tumors
<sup><xref ref-type="bibr" rid="ref-104">104</xref></sup>.</p>
<table-wrap id="T3" orientation="portrait" position="anchor">
<label>Table 3. </label>
<caption>
<title>Ongoing human clinical trials involving CRISPR/Cas9-based gene and cellular therapies.</title>
</caption>
<table content-type="article-table" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Condition</th>
<th align="left" colspan="1" rowspan="1" valign="top">Intervention</th>
<th align="left" colspan="1" rowspan="1" valign="top">Phase</th>
<th align="left" colspan="1" rowspan="1" valign="top">Type</th>
<th align="left" colspan="1" rowspan="1" valign="top">Primary objective and study
<break></break>design</th>
<th align="left" colspan="1" rowspan="1" valign="top">Principle</th>
<th align="left" colspan="1" rowspan="1" valign="top">Start date</th>
<th align="left" colspan="1" rowspan="1" valign="top">Finish date</th>
<th align="left" colspan="1" rowspan="1" valign="top">ClinicalTrials.
<break></break>gov identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Metastatic non-
<break></break>small cell lung
<break></break>cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: CRISPR/Cas9-
<break></break>mediated
<italic>PD-1</italic> knockout
<break></break>T cells from autologous origin
<break></break>Drug: cyclophosphamide,
<break></break>interleukin-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">A dose-escalation study to
<break></break>evaluate the safety of
<italic>ex vivo</italic>
<break></break>knocked-out, expanded,
<break></break>and selected
<italic>PD-1</italic> knockout
<break></break>engineered T cells that are
<break></break>infused back into the patient for
<break></break>the treatment of metastatic non-
<break></break>small cell lung cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target cancer
<break></break>cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">August 2016</td>
<td align="left" colspan="1" rowspan="1" valign="top">April 2018</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT02793856</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Muscle-invasive
<break></break>bladder cancer
<break></break>stage IV</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: CRISPR/Cas9-
<break></break>mediated
<italic>PD-1</italic> knockout
<break></break>T cells from autologous origin
<break></break>Drug: cyclophosphamide,
<break></break>interleukin-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">A dose-escalation study of
<break></break>
<italic>ex vivo</italic> knocked-out, expanded,
<break></break>and selected
<italic>PD-1</italic> knockout
<break></break>engineered T cells that are
<break></break>infused back into the patient for
<break></break>the treatment of muscle-invasive
<break></break>bladder cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target cancer
<break></break>cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">September
<break></break>2016</td>
<td align="left" colspan="1" rowspan="1" valign="top">September
<break></break>2019</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT02863913</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hormone-refractory
<break></break>prostate cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: CRISPR/Cas9-
<break></break>mediated
<italic>PD-1</italic> knockout
<break></break>T cells from autologous origin
<break></break>Drug: cyclophosphamide,
<break></break>interleukin-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">A dose-escalation study of
<break></break>
<italic>ex vivo</italic> knocked-out, expanded,
<break></break>and selected
<italic>PD-1</italic> knockout
<break></break>engineered T cells that are
<break></break>infused back into the patient
<break></break>for the treatment of castration-
<break></break>resistant prostate cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target cancer
<break></break>cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">November
<break></break>2016</td>
<td align="left" colspan="1" rowspan="1" valign="top">December
<break></break>2020</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT02867345</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Metastatic renal
<break></break>cell carcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: CRISPR/Cas9-
<break></break>mediated
<italic>PD-1</italic> knockout
<break></break>T cells from autologous origin
<break></break>Drug: cyclophosphamide,
<break></break>interleukin-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">A dose-escalation study of
<break></break>
<italic>ex vivo</italic> knocked-out, expanded,
<break></break>and selected
<italic>PD-1</italic> knockout
<break></break>engineered T cells that are
<break></break>infused back into the patient
<break></break>for the treatment of metastatic
<break></break>advanced renal cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target cancer
<break></break>cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">November
<break></break>2016</td>
<td align="left" colspan="1" rowspan="1" valign="top">November
<break></break>2020</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT02867332</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Advanced
<break></break>esophageal cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: CRISPR/Cas9-
<break></break>mediated
<italic>PD-1</italic> knockout
<break></break>T cells from autologous origin
<break></break>Drug: cyclophosphamide,
<break></break>interleukin-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Evaluate the safety of
<italic>ex vivo</italic>
<break></break>knocked-out, expanded, and
<break></break>selected
<italic>PD-1</italic> knockout T cells
<break></break>that are infused back into the
<break></break>patient for the treatment of
<break></break>advanced esophageal cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target cancer
<break></break>cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">March 2017</td>
<td align="left" colspan="1" rowspan="1" valign="top">December
<break></break>2018</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03081715</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gastric carcinoma
<break></break>stage IV,
<break></break>nasopharyngeal
<break></break>carcinoma stage IV,
<break></break>T-cell lymphoma
<break></break>stage IV, adult
<break></break>Hodgkin lymphoma
<break></break>stage IV, diffuse
<break></break>large B-cell
<break></break>lymphoma stage IV</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: CRISPR/Cas9-
<break></break>mediated
<italic>PD-1</italic> knockout
<break></break>T cells from autologous origin
<break></break>Drug: fludarabine,
<break></break>cyclophosphamide,
<break></break>interleukin-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1/2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Evaluate the safety and clinical
<break></break>response of cell therapy using
<break></break>CRISPR-Cas9-mediated
<italic>PD-1</italic>
<break></break>knockout EBV-CTL cells for the
<break></break>treatment of advanced-stage
<break></break>EBV-associated malignancies</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target EBV-
<break></break>associated
<break></break>cancer cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">April 2017</td>
<td align="left" colspan="1" rowspan="1" valign="top">March 2022</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03044743</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HIV-1-infection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: CRISPR/Cas9-
<break></break>mediated
<italic>CCR5</italic> modified
<break></break>CD34
<sup>+</sup> hematopoietic stem/
<break></break>progenitor cells from donors
<break></break>Drug: anti-retroviral therapy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Evaluate the safety and
<break></break>feasibility of allotransplantation
<break></break>with CRISPR/Cas9
<italic>CCR5</italic> gene
<break></break>modified CD34
<sup>+</sup> hematopoietic
<break></break>stem/progenitor cells in
<break></break>HIV-infected patients with
<break></break>hematological malignances</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target CCR5-
<break></break>positive
<break></break>immune cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">May 2017</td>
<td align="left" colspan="1" rowspan="1" valign="top">May 2021</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03164135</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">B-cell leukemia,
<break></break>B-cell lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: gene-disrupted
<break></break>allogeneic CD19-directed
<break></break>BBζ CAR-T cells (termed
<break></break>UCART019) will be
<break></break>generated by combining the
<break></break>lentiviral delivery of CAR and
<break></break>CRISPR RNA electroporation
<break></break>to disrupt endogenous
<italic>TCR</italic>
<break></break>and
<italic>B2M</italic> genes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1/2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Evaluate the feasibility, safety,
<break></break>and
<italic>in vivo</italic> persistence of
<break></break>UCART019 adoptively transferred
<break></break>T cells in patients with relapsed
<break></break>or refractory CD19
<sup>+</sup> leukemia and
<break></break>lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Target cancer
<break></break>cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">June 2017</td>
<td align="left" colspan="1" rowspan="1" valign="top">May 2022</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03166878</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Human
<break></break>papillomavirus-
<break></break>related malignant
<break></break>neoplasm</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: TALEN and
<break></break>CRISPR/Cas9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>In vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">An open-label and triple-cohort
<break></break>study to evaluate the safety and
<break></break>efficacy of TALEN and CRISPR/
<break></break>Cas9 plasmids for the treatment
<break></break>of HPV persistency and HPV-
<break></break>related cervical intraepithelial
<break></break>neoplasia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disrupt HPV
<break></break>E6/E7 DNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">January 2018</td>
<td align="left" colspan="1" rowspan="1" valign="top">January
<break></break>2019</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03057912</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neurofibromatosis
<break></break>type 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: establish isogenic
<break></break>
<italic>NF1</italic> wild-type (
<italic>NF1</italic>
<sup>+</sup>/
<sup>+</sup>),
<italic>NF1</italic>
<break></break>heterozygous (
<italic>NF1</italic>
<sup>+</sup>/
<sup>−</sup>), and
<break></break>
<italic>NF1</italic> homozygous (
<italic>NF1</italic>
<sup>−</sup>/
<sup>−</sup>)
<break></break>patient-specific iPSC
<break></break>lines using CRISPR/Cas9
<break></break>technology</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Establish an iPSC bank for disease
<break></break>phenotypic characterization,
<break></break>drug screening, and identification
<break></break>that can reverse or alleviate the
<break></break>disease phenotypes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Collection of
<break></break>stem cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">November
<break></break>2017</td>
<td align="left" colspan="1" rowspan="1" valign="top">June 2019</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03332030</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gastrointestinal
<break></break>infection</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biological: knockout CRISPR
<break></break>and gain-of-function CRISPR
<break></break>SAM
<break></break>Procedure: duodenal biopsy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>Ex vivo</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Identify and establish a list of
<break></break>host cellular proteins that mediate
<break></break>norovirus infection in a stem cell-
<break></break>derived human intestinal enteroid
<break></break>model</td>
<td align="left" colspan="1" rowspan="1" valign="top">Genome-
<break></break>wide genetic
<break></break>screening</td>
<td align="left" colspan="1" rowspan="1" valign="top">January 2018</td>
<td align="left" colspan="1" rowspan="1" valign="top">December
<break></break>2020</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03342547</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sickle cell disease</td>
<td align="left" colspan="1" rowspan="1" valign="top">Overall genetic literacy,
<break></break>CRISPR-specific literacy, and
<break></break>general attitudes and beliefs
<break></break>toward CRISPR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Observational</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cross-
<break></break>sectional</td>
<td align="left" colspan="1" rowspan="1" valign="top">Study the attitudes, beliefs, and
<break></break>opinions of those with SCD,
<break></break>parents of those with SCD, and
<break></break>providers on the use of CRISPR/
<break></break>Cas9 gene-editing</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="left" colspan="1" rowspan="1" valign="top">October 2017</td>
<td align="left" colspan="1" rowspan="1" valign="top">June 2018</td>
<td align="left" colspan="1" rowspan="1" valign="top">NCT03167450</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Based on ClinicalTrials.gov database on human clinical trials performed in the US and worldwide.
<italic>B2M</italic>, beta-2-microglobulin; CAR, chimeric antigen receptor;
<italic>CCR5</italic>, C-C chemokine receptor type 5; CTL, cytotoxic T-lymphocyte; EBV, Epstein-Barr virus; HPV, human papillomavirus; iPSC, induced pluripotent stem cell;
<italic>NF1</italic>, neurofibromatosis type 1;
<italic>PD-1</italic>, programmed cell death protein 1 gene; SCD, sickle cell disease; TALEN, transcription activator-like effector nuclease;
<italic>TCR</italic>, T-cell receptor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>These interventional studies aimed to evaluate the clinical response, safety, and maximal tolerant dose of the CRISPR-mediated
<italic>PD-1</italic> knockout T cells in treating advanced-stage malignancies upon being infused back into patients. An anti-cancer chemotherapy drug, cyclophosphamide, will be administered for a few days to modify the immune micro-environment before cell infusion or to deplete regulatory T cells (Tregs) before collecting peripheral blood. After cell infusion, the interleukin-2 cytokine that has both immune-modulating and anti-tumor properties will be administered to sustain the survival of infused T cells. For cancer immunotherapy of lymphoma or leukemia, an anti-metabolite anti-cancer chemotherapy drug, fludarabine, will be co-administered with the cyclophosphamide before cell infusion. Biomarkers and immunological markers will be closely monitored after cell infusion to determine whether the injections are causing any serious adverse effects and to evaluate whether the patients will receive benefits from the treatment.</p>
<p>In another CRISPR/Cas9-based
<italic>ex vivo</italic> gene therapy clinical trial, the CRISPR/Cas9 complex will be used to disrupt the C-C chemokine receptor type 5 (
<italic>CCR5</italic>) gene in the CD34
<sup>+</sup> hematopoietic stem or progenitor cells from donors (NCT03164135). Then, these
<italic>CCR5</italic> modified CD34
<sup>+</sup> cells from donors will be infused into the HIV-infected patients with AIDS and hematological malignancies. In principle, HIV-1 virus requires CCR5 receptor on the surface of host immune cells (for example, T cells) to infect the cell; hence, disrupting or blocking the CCR5 receptor may make the immune cell resistant to the virus infection. When the
<italic>CCR5</italic>-modified immune cells from the donor are mixed inside the body with the CCR5-positive immune cells from HIV-infected patients, the HIV-1 virus will infect and kill the CCR5-positive immune cells and the CCR5-negative immune cells will survive and eventually take over the immune function. The primary objectives of this clinical trial are to determine the safety of the allotransplantation of these CD34
<sup>+</sup> cells and to evaluate the resistance to the HIV-1 virus in HIV-infected patients after infusion of these CD34
<sup>+</sup> cells. Prior to the cell infusion, the patients will be treated with anti-retroviral therapy to achieve undetectable HIV-1 virus in the peripheral blood. During the follow-up, HIV-1 viral load, CD4
<sup>+</sup> T cells, and CCR5-negative cell counts in the peripheral blood will be monitored in HIV-infected patients.</p>
<p>Another promising
<italic>ex vivo</italic> gene therapy clinical trial is the combined use of CRISPR/Cas9 gene-editing technology and chimeric antigen receptor (CAR)-based cancer immunotherapy (NCT03166878). The CAR-expressed T cells can be engineered to recognize leukemia antigens such as CD19 on B cells for the treatment of relapsed or refractory B-cell malignancies. However, the cost and technical difficulties in the production and expansion of CAR-expressed T cells have hindered the wide application of personalized autologous CAR–T cell therapy. Thus, universal CAR–T cells derived from healthy unrelated donors are developed to overcome some of these drawbacks. To evade host-mediated immunity and deliver anti-leukemic effects without graft-versus-host disease in patients with relapsed or refractory B-cell malignancies, gene-disrupted allogeneic CD19-directed BBζ CAR–T cells (known as UCART019) are developed by combining the lentiviral delivery of CAR and CRISPR mRNA electroporation to disrupt both of the endogenous T-cell receptor (
<italic>TCR</italic>) and beta-2 microglobulin (
<italic>B2M</italic>) genes. The TCR and B2M play important roles in triggering the immune response; hence, disrupting both of these genes could minimize immunogenicity associated with allotransplantation. The primary goal of these allogeneic CD19 CAR–T cells is to evaluate the feasibility, safety, and
<italic>in vivo</italic> persistence of UCART019 adoptively transferred T cells in patients with relapsed or refractory CD19
<sup>+</sup> leukemia and lymphoma. The amount of UCART019 cells (engraftment), humoral host immunity, and anti-tumor response upon UCART019 cell infusions will be monitored.</p>
<p>Owing to the tissue complexities in humans, toxicity concern, and potential complications such as host immune response following a high dose of AAV vectors used to achieve significant therapeutic efficacy
<sup><xref ref-type="bibr" rid="ref-107">107</xref></sup>, the AAV-CRISPR viral delivery system is restricted to
<italic>ex vivo</italic> gene editing or genetic manipulation in animals. One of the promising strategies to overcome this issue was to mutagenize the surface-exposed tyrosine residues on the AAV capsid in order to avoid AAV degradation by the host cell proteasome machinery and to improve AAV intracellular trafficking to the nucleus, which can lead to high transduction efficiency at lower vector doses
<sup><xref ref-type="bibr" rid="ref-107">107</xref></sup>. The combined use of capsid-modified and genome-modified next-generation AAV vectors has allowed higher transduction efficiency and transgene expression at further reduced doses
<sup><xref ref-type="bibr" rid="ref-108">108</xref></sup>. To date, the AAV-CRISPR gene-editing system was tested in non-human animals only, but the first
<italic>in vivo</italic> gene therapy using CRISPR/Cas9 technology will be carried out in human clinical trials soon. In January 2018, an open-label and triple-cohort study will be conducted to evaluate the safety of therapeutic doses and the dosing regimen of CRISPR/Cas9 plasmid to treat human papillomavirus (HPV) persistency and HPV-related cervical intraepithelial neoplasia. Given the important roles that E6 and E7 play in HPV-driven carcinogenesis, CRISPR/Cas9-mediated disruption of HPV16 and HPV18 E6/E7 DNA could be an attractive approach for therapeutic interventions by significantly downregulating the expression of E6/E7 in order to induce HPV-associated cell apoptosis and to inhibit cell growth.</p>
</sec>
<sec>
<title>Promises and hurdles associated with the AAV-CRISPR system for future clinical applications</title>
<p>An increasing number of studies in mice have clearly demonstrated that the combined use of tissue-specific minimal promoters, natural and engineered AAV serotypes, different routes of administration, and small Cas9 orthologues enables efficient packaging and precise delivery of AAV-CRISPR vectors for targeted
<italic>in vivo</italic> genome editing in specific tissues with minimized side effects. Nevertheless, special considerations are required when selecting tissue-specific promoters, natural and engineered AAV serotypes, or routes of administration to avoid non-specific delivery and transgene expression of the AAV. In addition, the off-target effects, toxicity, and immunogenicity associated with CRISPR/Cas9 delivery remain to be fully resolved.</p>
<sec>
<title>Non-specific delivery and transgene expression</title>
<p>Tissue-specific promoters and AAV serotypes might still be able to transduce and induce transgene expression in healthy tissues or other non-target organs if a strong promoter or a high dose of viral vectors is introduced into the body by intravenous injection. Despite a significant improvement in the efficiency and specificity of newly discovered natural and engineered AAV variants for systemic delivery in mice, the toxicity and side effects associated with the non-specific delivery of the transgenes to the non-target tissues and organs remain a concern
<sup><xref ref-type="bibr" rid="ref-13">13</xref>,
<xref ref-type="bibr" rid="ref-89">89</xref></sup>. It is easier to get delivery vehicles taken up by liver than other organs upon systemic injection. Therefore, it is more challenging to specifically target non-liver organs than liver via a systemic delivery approach. For instance, recently discovered synthetic vectors, AAV-PHP.B
<sup><xref ref-type="bibr" rid="ref-13">13</xref></sup> and tyrosine-mutant AAV
<sup><xref ref-type="bibr" rid="ref-89">89</xref></sup>, were found to transduce the adult mouse central nervous system more efficiently and widely than the natural AAV9 after intravenous injection. However, these synthetic vectors can also transduce the liver and other peripheral organs upon systemic delivery
<sup><xref ref-type="bibr" rid="ref-13">13</xref>,
<xref ref-type="bibr" rid="ref-89">89</xref></sup>. In this case, local injections such as stereotaxic injection into the brain can minimize the possible complications or adverse side effects associated with non-specific expression of CRISPR in healthy tissues or other non-target organs.</p>
</sec>
<sec>
<title>Off-target effects</title>
<p>Even though CRISPR/Cas9 predominantly recognizes the intended target sites, a series of high-throughput genome-wide methods such as multiplex Digenome-seq
<sup><xref ref-type="bibr" rid="ref-109">109</xref>,
<xref ref-type="bibr" rid="ref-110">110</xref></sup>, ChIP-seq
<sup><xref ref-type="bibr" rid="ref-111">111</xref>,
<xref ref-type="bibr" rid="ref-112">112</xref></sup>, GUIDE-seq
<sup><xref ref-type="bibr" rid="ref-113">113</xref></sup>, and whole-genome sequencing
<sup><xref ref-type="bibr" rid="ref-114">114</xref></sup> as well as targeted deep sequencing
<sup><xref ref-type="bibr" rid="ref-112">112</xref></sup>, Cas9 toxicity screens
<sup><xref ref-type="bibr" rid="ref-115">115</xref></sup>, and SITE-seq biochemical methods
<sup><xref ref-type="bibr" rid="ref-116">116</xref></sup> have revealed evidence of off-target effects due to target mismatch tolerance of CRISPR/Cas9. As inter-individual natural genetic variation can affect CRISPR/Cas9 specificity
<sup><xref ref-type="bibr" rid="ref-117">117</xref></sup>, a recently developed CIRCLE-seq approach could be used to identify genome-wide off-target mutations of CRISPR/Cas9 that are associated with cell type-specific single-nucleotide polymorphisms to provide personalized specificity profiles
<sup><xref ref-type="bibr" rid="ref-118">118</xref></sup>. Notably, given the same target sequence of gRNA, off-target sites of Cas9 before and after being fused to a catalytic enzyme (for example, cytidine deaminase base editor and chromatin modifiers) could be different; therefore, independent assessment of their genome-wide specificities is recommended
<sup><xref ref-type="bibr" rid="ref-119">119</xref></sup>. Imprecise repair of Cas9-induced DNA double-stranded breaks can give rise to deleterious structural chromosomal rearrangements such as deletions, inversions, and translocations, which in turn may activate oncogenes or cause genome instability
<sup><xref ref-type="bibr" rid="ref-120">120</xref></sup>. Hence, high-throughput screenings of CRISPR/Cas9 off-target activity and further improvement in the fidelity of CRISPR/Cas9 on-target activity are essential for safety in clinical gene transfer applications.
<bold></bold>
</p>
<p>There are many ways to minimize CRISPR/Cas9 off-target effects in the human genome. For example, a recently developed RNA-targeting Cas9 (RCas9) system could avoid permanent off-target genetic lesions in DNA-mediated CRISPR-based therapeutics
<sup><xref ref-type="bibr" rid="ref-121">121</xref></sup>. The RCas9 system consists of a fusion of rationally truncated dCas9 protein and PilT N-terminus (PIN) domain that can be packaged into the AAV vector for eliminating toxic microsatellite repeat expansion RNA or reducing repetitive RNA level without targeting the DNA
<sup><xref ref-type="bibr" rid="ref-121">121</xref></sup>. With a similar strategy, systemic delivery of dCas9/gRNA by AAV9 significantly reduced pathological RNA foci, rescued chloride channel 1 protein expression, and decreased myotonia in myotonic dystrophy mice by impeding the transcription of expanded microsatellite repeats
<sup><xref ref-type="bibr" rid="ref-122">122</xref></sup>. Another way is to deliver purified Cas9 RNPs rather than plasmid expression vectors
<sup><xref ref-type="bibr" rid="ref-10">10</xref>,
<xref ref-type="bibr" rid="ref-123">123</xref></sup>. Despite some technical constraints in non-viral delivery methods for
<italic>in vivo</italic> administration, the use of Cas9 RNPs can limit the duration of Cas9 expression and decrease the chance of Cas9 nuclease cleaving at non-specific sites in a genome because of the rapid clearance from the cell
<sup><xref ref-type="bibr" rid="ref-10">10</xref>,
<xref ref-type="bibr" rid="ref-123">123</xref></sup>. Complementing the CRISPR-based editing capability with conditional genetic manipulation tools such as photoactivatable Cas9
<sup><xref ref-type="bibr" rid="ref-124">124</xref>,
<xref ref-type="bibr" rid="ref-125">125</xref></sup>, chemical-inducible Cas9
<sup><xref ref-type="bibr" rid="ref-126">126</xref>,
<xref ref-type="bibr" rid="ref-127">127</xref></sup>, or multiple inputs logic gate genetic circuits
<sup><xref ref-type="bibr" rid="ref-128">128</xref>,
<xref ref-type="bibr" rid="ref-129">129</xref></sup> enables the precise spatial and temporal control of Cas9 activity inside the cell, which in turn leads to the reduction in off-target activity. Alternatively, a pair of Cas9 nickases
<sup><xref ref-type="bibr" rid="ref-130">130</xref>–
<xref ref-type="bibr" rid="ref-132">132</xref></sup>, dCas9-FokI
<sup><xref ref-type="bibr" rid="ref-133">133</xref></sup>, or high-fidelity Cas9 variants such as SpCas9-HF1
<sup><xref ref-type="bibr" rid="ref-134">134</xref></sup>, eSpCas9
<sup><xref ref-type="bibr" rid="ref-135">135</xref></sup>, and HypaCas9
<sup><xref ref-type="bibr" rid="ref-136">136</xref></sup> can be used to minimize undesired off-target mutagenesis.</p>
<p>The use of a scarless genome-editing strategy for targeted point mutation knock-in can also minimize unwanted mutation formations to favor the desired clean base editing outcomes
<sup><xref ref-type="bibr" rid="ref-137">137</xref>,
<xref ref-type="bibr" rid="ref-138">138</xref></sup>. For a point mutation knock-in, the efficiency of precise sequence replacement by CRISPR-mediated homology-directed repair (HDR) could be significantly increased by using asymmetric donor DNA
<sup><xref ref-type="bibr" rid="ref-139">139</xref></sup>, HDR enhancer
<sup><xref ref-type="bibr" rid="ref-140">140</xref></sup>, or short ssDNA donor oligonucleotides as a donor template instead of long plasmid donor
<sup><xref ref-type="bibr" rid="ref-139">139</xref></sup> or by inhibiting non-homologous end joining (NHEJ) activity
<sup><xref ref-type="bibr" rid="ref-141">141</xref></sup>. Also, the artificial chimeric RNAs
<sup><xref ref-type="bibr" rid="ref-142">142</xref></sup>—truncated
<sup><xref ref-type="bibr" rid="ref-73">73</xref>,
<xref ref-type="bibr" rid="ref-113">113</xref></sup> and chemically modified
<sup><xref ref-type="bibr" rid="ref-143">143</xref></sup> gRNAs—were shown to have lower off-target activity than the original gRNAs. A number of bioinformatics analysis tools such as GuideScan
<sup><xref ref-type="bibr" rid="ref-144">144</xref></sup>, CRISPRdirect
<sup><xref ref-type="bibr" rid="ref-145">145</xref></sup>, and Cas-OFFinder
<sup><xref ref-type="bibr" rid="ref-146">146</xref></sup> permit the specific design of gRNAs to avoid binding at the non-intended target sites in the human genome. The specificity of the gRNA designed can be improved by selecting a target sequence with two Gs at the 5′ terminus
<sup><xref ref-type="bibr" rid="ref-131">131</xref></sup> and avoiding potential mismatches at the seed sequence or base-pairing adjacent to the PAM
<sup><xref ref-type="bibr" rid="ref-147">147</xref></sup>. Another innovative way to improve the specificity and reduce the toxicity of the CRISPR/Cas9 is co-delivery of DNA decoys or competitive inhibitor oligonucleotides bearing all possible off-target sequences that can sequester and prevent the CRISPR/Cas9 from binding to the off-target sites within a host genome. A similar concept has been successfully demonstrated to alleviate the off-target effects of RNA interference by using RNA decoys to reduce the sense strand activity of shRNAs
<sup><xref ref-type="bibr" rid="ref-148">148</xref></sup>, while artificial microRNA (miRNA) sponges have been used to inhibit miRNA function and its ability to regulate natural mRNAs
<sup><xref ref-type="bibr" rid="ref-149">149</xref></sup>. In addition, a recently developed miRNA-responsive CRISPR/Cas9 switch could be useful for cell type-specific genome editing by sensing endogenous miRNA activities
<sup><xref ref-type="bibr" rid="ref-150">150</xref></sup>.</p>
</sec>
<sec>
<title>Immunogenicity</title>
<p>Owing to the exogenous nature of AAV and CRISPR components, host immune responses can attenuate therapeutic effects and cause side effects. Thus, the toxicity and immunogenicity associated with AAV and CRISPR components should be circumvented for safer and higher efficacy in clinical gene therapy applications. Even though the AAV generally elicits a very mild immune response and does not induce extensive cellular damage
<italic>in vivo</italic>, certain AAV serotypes such as AAV9 may evoke humoral immune responses, as indicated by the presence of capsid-specific antibodies
<sup><xref ref-type="bibr" rid="ref-50">50</xref></sup>. While transient immunosuppression is one of the possible ways to mitigate the host immune response following the delivery of AAV vectors
<sup><xref ref-type="bibr" rid="ref-151">151</xref></sup>, it is not feasible for long-term therapeutic treatments of chronic diseases and is prone to adverse complications such as infections and malignancies. Empty capsid mutants can be used as decoys to overcome pre-existing humoral immunity by adsorbing antibodies in the bloodstream upon systemic delivery of both empty and functional AAVs
<sup><xref ref-type="bibr" rid="ref-152">152</xref></sup>. Alternatively, the AAV capsids can be genetically engineered or mutated to reduce the binding affinity and the neutralizing effects of AAV antibodies
<sup><xref ref-type="bibr" rid="ref-15">15</xref>,
<xref ref-type="bibr" rid="ref-153">153</xref>–
<xref ref-type="bibr" rid="ref-155">155</xref></sup>. In addition to AAVs, the presence of Cas9-specific antibodies in Cas9-exposed animals indicated that Cas9 could evoke deleterious cellular and humoral immune responses
<italic>in vivo</italic>
<sup><xref ref-type="bibr" rid="ref-50">50</xref></sup>. Expression of Cas9
<italic>in vivo</italic> could affect the transcription of the genes associated with the immunological processes. This in turn may destabilize the host immune system, elicit significant cellular infiltration or expansion, and induce enlargement of the draining lymph nodes with increased immune cell counts
<sup><xref ref-type="bibr" rid="ref-50">50</xref></sup>. The Cas9-responsive T-cell clonotype described previously could serve as a distinctive biomarker to assess Cas9-specific immunity before clinical implementation of the CRISPR system
<sup><xref ref-type="bibr" rid="ref-50">50</xref></sup>. To minimize the immune response due to prolonged expression of Cas9, conditional genome editing with the self-limiting CRISPR/Cas9 system
<sup><xref ref-type="bibr" rid="ref-58">58</xref></sup> or light-inducible
<sup><xref ref-type="bibr" rid="ref-124">124</xref>,
<xref ref-type="bibr" rid="ref-125">125</xref></sup> or chemical-inducible
<sup><xref ref-type="bibr" rid="ref-126">126</xref>,
<xref ref-type="bibr" rid="ref-127">127</xref></sup> Cas9 can be used to minimize the duration of Cas9 expression in the body.</p>
</sec>
</sec>
<sec>
<title>Conclusions and perspectives</title>
<p>The AAV-CRISPR system holds enormous translational potential to develop curative therapeutic options for patients with severe and life-threatening genetic diseases by permanently editing disease-causing or risk genes in the human body. The delivery, efficacy, and safety issues in treating complex heritable and somatic disorders have to be fully resolved to fulfill this promise. Thus far, the
<italic>ex vivo</italic> approach has been adopted to overcome the technical challenges associated with the
<italic>in vivo</italic> delivery of the AAV-CRISPR viral vectors in humans. The
<italic>ex vivo</italic> gene-editing approach is commonly used for the therapeutic treatment of blood disorders, cancers, and immune-related diseases. In the near future,
<italic>in vivo</italic> genome editing is expected to offer better avenues to treat a wide range of human hereditary diseases in adults.
<italic>In vivo</italic> gene therapy in humans provides several advantages over the
<italic>ex vivo</italic> approach, and sometimes a combination of the two is necessary to achieve a good therapeutic outcome. For example,
<italic>in vivo</italic> photoreceptor cell rescue can be used to halt retinal degeneration to preserve existing vision, while
<italic>ex vivo</italic> photoreceptor cell replacement can be used to restore lost vision in patients with retinal dystrophy
<sup><xref ref-type="bibr" rid="ref-156">156</xref></sup>. After
<italic>in vivo</italic> photoreceptor cell rescue, the retinal environment may become more permissive for transplanted photo-receptor survival and
<italic>de novo</italic> synaptogenesis via the
<italic>ex vivo</italic> approach
<sup><xref ref-type="bibr" rid="ref-156">156</xref></sup>.</p>
<p>The AAV vector already has a long history of success in clinical trials
<italic>in vivo</italic>, but owing to the relatively recent arrival of CRISPR technology, the AAV-CRISPR system has yet to be tested
<italic>in vivo</italic> for human gene therapy trials. Nevertheless, three ongoing human clinical trials (NCT03041324, NCT02702115, and NCT02695160) have used AAV vectors to deliver zinc finger nucleases, an earlier and well-established gene-editing tool, to the liver tissue for the treatment of hemophilia B and mucopolysaccharidosis. Similarly, the AAV vectors may be used for CRISPR delivery for human clinical trials in the future. Excitingly, the first
<italic>in vivo</italic> human gene therapy trials using CRISPR/Cas9 plasmid administration to treat human HPV-related malignant neoplasms will be initiated in January 2018 (NCT03057912).</p>
<p>Although it is more feasible to deliver the transgene
<italic>ex vivo</italic> than
<italic>in vivo</italic>, the
<italic>in vivo</italic> approach eliminates the need for cell transplants. Therefore,
<italic>in vivo</italic> therapy can avoid potential graft-versus-host disease and immunosuppression-related complications such as infections and malignancies, as seen in cellular therapy. Recently, various genetically engineered AAV variants or structure-guided derivations of AAV mutants have been developed to significantly improve the efficiency and specificity for
<italic>in vivo</italic> delivery
<sup><xref ref-type="bibr" rid="ref-157">157</xref></sup>. Compared with existing AAV serotypes, these newly engineered AAV capsids enabled higher transduction efficiency at a targeted tissue by altering the native tropism of the AAV capsid
<sup><xref ref-type="bibr" rid="ref-13">13</xref>–
<xref ref-type="bibr" rid="ref-15">15</xref>,
<xref ref-type="bibr" rid="ref-158">158</xref></sup> and had low immunogenicity by evading pre-existing anti-AAV capsid neutralizing antibodies in the human body
<sup><xref ref-type="bibr" rid="ref-159">159</xref>,
<xref ref-type="bibr" rid="ref-160">160</xref></sup>. Given the encouraging results obtained with the next-generation synthetic AAV capsids in animals, this synthetic AAV vector may also be used to deliver CRISPR/Cas9 transgene in humans for
<italic>in vivo</italic> genome editing in the near future. Further improvement in the performance of engineered AAV variants and CRISPR components is necessary to realize the full potential of the AAV-CRISPR system for
<italic>in vivo</italic> genome editing.</p>
</sec>
</body>
<back>
<ref-list>
<ref id="ref-1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lau</surname><given-names>CH</given-names></name><name><surname>Suh</surname><given-names>Y</given-names></name></person-group>:
<article-title>Genome and Epigenome Editing in Mechanistic Studies of Human Aging and Aging-Related Disease.</article-title>
<source/><italic>Gerontology.</italic>
<year>2017</year>;<volume>63</volume>(<issue>2</issue>):<fpage>103</fpage>–<lpage>17</lpage>.
<pub-id pub-id-type="doi">10.1159/000452972</pub-id>
<!--<pub-id pub-id-type="pmcid">5310972</pub-id>-->
<pub-id pub-id-type="pmid">27974723</pub-id></mixed-citation>
</ref>
<ref id="ref-2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barrangou</surname><given-names>R</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name></person-group>:
<article-title>Applications of CRISPR technologies in research and beyond.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2016</year>;<volume>34</volume>(<issue>9</issue>):<fpage>933</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3659</pub-id>
<pub-id pub-id-type="pmid">27606440</pub-id></mixed-citation>
</ref>
<ref id="ref-3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Multiplex genome engineering using CRISPR/Cas systems.</article-title>
<source/><italic>Science.</italic>
<year>2013</year>;<volume>339</volume>(<issue>6121</issue>):<fpage>819</fpage>–<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1126/science.1231143</pub-id>
<!--<pub-id pub-id-type="pmcid">3795411</pub-id>-->
<pub-id pub-id-type="pmid">23287718</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717969062">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>WX</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> genome editing using
<italic>Staphylococcus aureus</italic> Cas9.</article-title>
<source/><italic>Nature.</italic>
<year>2015</year>;<volume>520</volume>(<issue>7546</issue>):<fpage>186</fpage>–<lpage>91</lpage>.
<pub-id pub-id-type="doi">10.1038/nature14299</pub-id>
<!--<pub-id pub-id-type="pmcid">4393360</pub-id>-->
<pub-id pub-id-type="pmid">25830891</pub-id></mixed-citation>
</ref>
<ref id="ref-5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Koo</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> genome editing with a small Cas9 orthologue derived from
<italic>Campylobacter jejuni</italic>.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2017</year>;<volume>8</volume>:<fpage>14500</fpage>.
<pub-id pub-id-type="doi">10.1038/ncomms14500</pub-id>
<!--<pub-id pub-id-type="pmcid">5473640</pub-id>-->
<pub-id pub-id-type="pmid">28220790</pub-id></mixed-citation>
</ref>
<ref id="ref-6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Komor</surname><given-names>AC</given-names></name><name><surname>Badran</surname><given-names>AH</given-names></name><name><surname>Liu</surname><given-names>DR</given-names></name></person-group>:
<article-title>CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.</article-title>
<source/><italic>Cell.</italic>
<year>2017</year>;<volume>168</volume>(<issue>1–2</issue>):<fpage>20</fpage>–<lpage>36</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2016.10.044</pub-id>
<!--<pub-id pub-id-type="pmcid">5235943</pub-id>-->
<pub-id pub-id-type="pmid">27866654</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726984195">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>WA</given-names></name><etal></etal></person-group>:
<article-title>CRISPR/Cas9 for Human Genome Engineering and Disease Research.</article-title>
<source/><italic>Annu Rev Genomics Hum Genet.</italic>
<year>2016</year>;<volume>17</volume>:<fpage>131</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1146/annurev-genom-083115-022258</pub-id>
<pub-id pub-id-type="pmid">27216776</pub-id></mixed-citation>
</ref>
<ref id="ref-8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kouranova</surname><given-names>E</given-names></name><name><surname>Forbes</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell Embryos.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>2016</year>;<volume>27</volume>(<issue>6</issue>):<fpage>464</fpage>–<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.2016.009</pub-id>
<!--<pub-id pub-id-type="pmcid">4931306</pub-id>-->
<pub-id pub-id-type="pmid">27094534</pub-id></mixed-citation>
</ref>
<ref id="ref-9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.</article-title>
<source/><italic>J Biotechnol.</italic>
<year>2015</year>;<volume>208</volume>:<fpage>44</fpage>–<lpage>53</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jbiotec.2015.04.024</pub-id>
<pub-id pub-id-type="pmid">26003884</pub-id></mixed-citation>
</ref>
<ref id="ref-10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>SW</given-names></name><etal></etal></person-group>:
<article-title>Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins.</article-title>
<source/><italic>Genome Res.</italic>
<year>2014</year>;<volume>24</volume>(<issue>6</issue>):<fpage>1012</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.171322.113</pub-id>
<!--<pub-id pub-id-type="pmcid">4032847</pub-id>-->
<pub-id pub-id-type="pmid">24696461</pub-id></mixed-citation>
</ref>
<ref id="ref-11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Zalesky</surname><given-names>A</given-names></name><name><surname>Breakspear</surname><given-names>M</given-names></name></person-group>:
<article-title>The connectomics of brain disorders.</article-title>
<source/><italic>Nat Rev Neurosci.</italic>
<year>2015</year>;<volume>16</volume>(<issue>3</issue>):<fpage>159</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1038/nrn3901</pub-id>
<pub-id pub-id-type="pmid">25697159</pub-id></mixed-citation>
</ref>
<ref id="ref-12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Staahl</surname><given-names>BT</given-names></name><name><surname>Benekareddy</surname><given-names>M</given-names></name><name><surname>Coulon-Bainier</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2017</year>;<volume>35</volume>(<issue>5</issue>):<fpage>431</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3806</pub-id>
<pub-id pub-id-type="pmid">28191903</pub-id></mixed-citation>
</ref>
<ref id="ref-13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deverman</surname><given-names>BE</given-names></name><name><surname>Pravdo</surname><given-names>PL</given-names></name><name><surname>Simpson</surname><given-names>BP</given-names></name><etal></etal></person-group>:
<article-title>Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2016</year>;<volume>34</volume>(<issue>2</issue>):<fpage>204</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3440</pub-id>
<!--<pub-id pub-id-type="pmcid">5088052</pub-id>-->
<pub-id pub-id-type="pmid">26829320</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726112855">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>SR</given-names></name><name><surname>Harris</surname><given-names>AF</given-names></name><name><surname>Cabral</surname><given-names>DJ</given-names></name><etal></etal></person-group>:
<article-title>Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2016</year>;<volume>24</volume>(<issue>4</issue>):<fpage>726</fpage>–<lpage>35</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2015.231</pub-id>
<!--<pub-id pub-id-type="pmcid">4886933</pub-id>-->
<pub-id pub-id-type="pmid">26708003</pub-id></mixed-citation>
</ref>
<ref id="ref-15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>SR</given-names></name><name><surname>Fitzpatrick</surname><given-names>Z</given-names></name><name><surname>Harris</surname><given-names>AF</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2016</year>;<volume>24</volume>(<issue>7</issue>):<fpage>1247</fpage>–<lpage>57</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2016.84</pub-id>
<!--<pub-id pub-id-type="pmcid">5088762</pub-id>-->
<pub-id pub-id-type="pmid">27117222</pub-id></mixed-citation>
</ref>
<ref id="ref-16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Kauffman</surname><given-names>KJ</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name></person-group>:
<article-title>Delivery technologies for genome editing.</article-title>
<source/><italic>Nat Rev Drug Discov.</italic>
<year>2017</year>;<volume>16</volume>(<issue>6</issue>):<fpage>387</fpage>–<lpage>99</lpage>.
<pub-id pub-id-type="doi">10.1038/nrd.2016.280</pub-id>
<pub-id pub-id-type="pmid">28337020</pub-id></mixed-citation>
</ref>
<ref id="ref-17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name></person-group>:
<article-title>The CRISPR/Cas9 system: Their delivery,
<italic>in vivo</italic> and
<italic>ex vivo</italic> applications and clinical development by startups.</article-title>
<source/><italic>Biotechnol Prog.</italic>
<year>2017</year>;<volume>33</volume>(<issue>4</issue>):<fpage>1035</fpage>–<lpage>45</lpage>.
<pub-id pub-id-type="doi">10.1002/btpr.2484</pub-id>
<pub-id pub-id-type="pmid">28440027</pub-id></mixed-citation>
</ref>
<ref id="ref-18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>He</surname><given-names>ZY</given-names></name><name><surname>Men</surname><given-names>K</given-names></name><name><surname>Qin</surname><given-names>Z</given-names></name><etal></etal></person-group>:
<article-title>Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.</article-title>
<source/><italic>Sci China Life Sci.</italic>
<year>2017</year>;<volume>60</volume>(<issue>5</issue>):<fpage>458</fpage>–<lpage>67</lpage>.
<pub-id pub-id-type="doi">10.1007/s11427-017-9033-0</pub-id>
<pub-id pub-id-type="pmid">28527117</pub-id></mixed-citation>
</ref>
<ref id="ref-19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>MR</given-names></name><name><surname>Fricano-Kugler</surname><given-names>CJ</given-names></name><name><surname>Getz</surname><given-names>SA</given-names></name><etal></etal></person-group>:
<article-title>A Retroviral CRISPR-Cas9 System for Cellular Autism-Associated Phenotype Discovery in Developing Neurons.</article-title>
<source/><italic>Sci Rep.</italic>
<year>2016</year>;<volume>6</volume>:<fpage>25611</fpage>.
<pub-id pub-id-type="doi">10.1038/srep25611</pub-id>
<!--<pub-id pub-id-type="pmcid">4861960</pub-id>-->
<pub-id pub-id-type="pmid">27161796</pub-id></mixed-citation>
</ref>
<ref id="ref-20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koike-Yusa</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>EP</given-names></name><etal></etal></person-group>:
<article-title>Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2014</year>;<volume>32</volume>(<issue>3</issue>):<fpage>267</fpage>–<lpage>73</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.2800</pub-id>
<pub-id pub-id-type="pmid">24535568</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718276719">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kabadi</surname><given-names>AM</given-names></name><name><surname>Ousterout</surname><given-names>DG</given-names></name><name><surname>Hilton</surname><given-names>IB</given-names></name><etal></etal></person-group>:
<article-title>Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.</article-title>
<source/><italic>Nucleic Acids Res.</italic>
<year>2014</year>;<volume>42</volume>(<issue>19</issue>):<fpage>e147</fpage>.
<pub-id pub-id-type="doi">10.1093/nar/gku749</pub-id>
<!--<pub-id pub-id-type="pmcid">4231726</pub-id>-->
<pub-id pub-id-type="pmid">25122746</pub-id></mixed-citation>
</ref>
<ref id="ref-22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>2015</year>;<volume>26</volume>(<issue>7</issue>):<fpage>432</fpage>–<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.2015.087</pub-id>
<!--<pub-id pub-id-type="pmcid">4509492</pub-id>-->
<pub-id pub-id-type="pmid">26086867</pub-id></mixed-citation>
</ref>
<ref id="ref-23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>R</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9.</article-title>
<source/><italic>FEBS Lett.</italic>
<year>2014</year>;<volume>588</volume>(<issue>21</issue>):<fpage>3954</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.febslet.2014.09.008</pub-id>
<pub-id pub-id-type="pmid">25241167</pub-id></mixed-citation>
</ref>
<ref id="ref-24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Grimm</surname><given-names>D</given-names></name></person-group>:
<article-title>CRISPR genome engineering and viral gene delivery: a case of mutual attraction.</article-title>
<source/><italic>Biotechnol J.</italic>
<year>2015</year>;<volume>10</volume>(<issue>2</issue>):<fpage>258</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1002/biot.201400529</pub-id>
<pub-id pub-id-type="pmid">25663455</pub-id></mixed-citation>
</ref>
<ref id="ref-25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swiech</surname><given-names>L</given-names></name><name><surname>Heidenreich</surname><given-names>M</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> interrogation of gene function in the mammalian brain using CRISPR-Cas9.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2015</year>;<volume>33</volume>(<issue>1</issue>):<fpage>102</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3055</pub-id>
<!--<pub-id pub-id-type="pmcid">4492112</pub-id>-->
<pub-id pub-id-type="pmid">25326897</pub-id></mixed-citation>
</ref>
<ref id="ref-26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>M</given-names></name><name><surname>Ehsaei</surname><given-names>Z</given-names></name><name><surname>Taylor</surname><given-names>V</given-names></name><etal></etal></person-group>:
<article-title>Baculovirus-based genome editing in primary cells.</article-title>
<source/><italic>Plasmid.</italic>
<year>2017</year>;<volume>90</volume>:<fpage>5</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.plasmid.2017.01.003</pub-id>
<pub-id pub-id-type="pmid">28119062</pub-id></mixed-citation>
</ref>
<ref id="ref-27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>M</given-names></name><name><surname>Bellon-Echeverria</surname><given-names>I</given-names></name><name><surname>Rizk</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Highly efficient baculovirus-mediated multigene delivery in primary cells.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2016</year>;<volume>7</volume>:<fpage>11529</fpage>.
<pub-id pub-id-type="doi">10.1038/ncomms11529</pub-id>
<!--<pub-id pub-id-type="pmcid">4857464</pub-id>-->
<pub-id pub-id-type="pmid">27143231</pub-id></mixed-citation>
</ref>
<ref id="ref-28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Gonçalves</surname><given-names>MA</given-names></name></person-group>:
<article-title>Engineered Viruses as Genome Editing Devices.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2016</year>;<volume>24</volume>(<issue>3</issue>):<fpage>447</fpage>–<lpage>57</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2015.164</pub-id>
<!--<pub-id pub-id-type="pmcid">4786910</pub-id>-->
<pub-id pub-id-type="pmid">26336974</pub-id></mixed-citation>
</ref>
<ref id="ref-29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwang</surname><given-names>TW</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group>:
<article-title>Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials.</article-title>
<source/><italic>Mol Ther Methods Clin Dev.</italic>
<year>2016</year>;<volume>3</volume>:<fpage>15050</fpage>.
<pub-id pub-id-type="doi">10.1038/mtm.2015.50</pub-id>
<!--<pub-id pub-id-type="pmcid">4729316</pub-id>-->
<pub-id pub-id-type="pmid">26858963</pub-id></mixed-citation>
</ref>
<ref id="ref-30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Epstein</surname><given-names>BE</given-names></name><name><surname>Schaffer</surname><given-names>DV</given-names></name></person-group>:
<article-title>Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing.</article-title>
<source/><italic>Adv Exp Med Biol.</italic>
<year>2017</year>;<volume>1016</volume>:<fpage>29</fpage>–<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1007/978-3-319-63904-8_2</pub-id>
<!--<pub-id pub-id-type="pmcid">5702533</pub-id>-->
<pub-id pub-id-type="pmid">29130152</pub-id></mixed-citation>
</ref>
<ref id="ref-31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mingozzi</surname><given-names>F</given-names></name><name><surname>High</surname><given-names>KA</given-names></name></person-group>:
<article-title>Therapeutic
<italic>in vivo</italic> gene transfer for genetic disease using AAV: progress and challenges.</article-title>
<source/><italic>Nat Rev Genet.</italic>
<year>2011</year>;<volume>12</volume>(<issue>5</issue>):<fpage>341</fpage>–<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1038/nrg2988</pub-id>
<pub-id pub-id-type="pmid">21499295</pub-id></mixed-citation>
</ref>
<ref id="ref-32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Senís</surname><given-names>E</given-names></name><name><surname>Fatouros</surname><given-names>C</given-names></name><name><surname>Große</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.</article-title>
<source/><italic>Biotechnol J.</italic>
<year>2014</year>;<volume>9</volume>(<issue>11</issue>):<fpage>1402</fpage>–<lpage>12</lpage>.
<pub-id pub-id-type="doi">10.1002/biot.201400046</pub-id>
<pub-id pub-id-type="pmid">25186301</pub-id></mixed-citation>
</ref>
<ref id="ref-33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Goh</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells.</article-title>
<source/><italic>Nucleic Acids Res.</italic>
<year>2013</year>;<volume>41</volume>(<issue>19</issue>):<fpage>e180</fpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkt721</pub-id>
<!--<pub-id pub-id-type="pmcid">3799456</pub-id>-->
<pub-id pub-id-type="pmid">23945944</pub-id></mixed-citation>
</ref>
<ref id="ref-34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Konermann</surname><given-names>S</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><etal></etal></person-group>:
<article-title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.</article-title>
<source/><italic>Nat Protoc.</italic>
<year>2017</year>;<volume>12</volume>(<issue>4</issue>):<fpage>828</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1038/nprot.2017.016</pub-id>
<!--<pub-id pub-id-type="pmcid">5526071</pub-id>-->
<pub-id pub-id-type="pmid">28333914</pub-id></mixed-citation>
</ref>
<ref id="ref-35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klann</surname><given-names>TS</given-names></name><name><surname>Black</surname><given-names>JB</given-names></name><name><surname>Chellappan</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2017</year>;<volume>35</volume>(<issue>6</issue>):<fpage>561</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3853</pub-id>
<!--<pub-id pub-id-type="pmcid">5462860</pub-id>-->
<pub-id pub-id-type="pmid">28369033</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727471219">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morris</surname><given-names>SJ</given-names></name><name><surname>Turner</surname><given-names>AV</given-names></name><name><surname>Green</surname><given-names>N</given-names></name><etal></etal></person-group>:
<article-title>Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines.</article-title>
<source/><italic>Methods Mol Biol.</italic>
<year>2016</year>;<volume>1349</volume>:<fpage>121</fpage>–<lpage>35</lpage>.
<pub-id pub-id-type="doi">10.1007/978-1-4939-3008-1_8</pub-id>
<pub-id pub-id-type="pmid">26458833</pub-id></mixed-citation>
</ref>
<ref id="ref-37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garnier</surname><given-names>A</given-names></name><name><surname>Côté</surname><given-names>J</given-names></name><name><surname>Nadeau</surname><given-names>I</given-names></name><etal></etal></person-group>:
<article-title>Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells.</article-title>
<source/><italic>Cytotechnology.</italic>
<year>1994</year>;<volume>15</volume>(<issue>1–3</issue>):<fpage>145</fpage>–<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1007/BF00762389</pub-id>
<pub-id pub-id-type="pmid">7765926</pub-id></mixed-citation>
</ref>
<ref id="ref-38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fricano-Kugler</surname><given-names>CJ</given-names></name><name><surname>Williams</surname><given-names>MR</given-names></name><name><surname>Salinaro</surname><given-names>JR</given-names></name><etal></etal></person-group>:
<article-title>Designing, Packaging, and Delivery of High Titer CRISPR Retro and Lentiviruses via Stereotaxic Injection.</article-title>
<source/><italic>J Vis Exp.</italic>
<year>2016</year>; (<issue>111</issue>).
<pub-id pub-id-type="doi">10.3791/53783</pub-id>
<!--<pub-id pub-id-type="pmcid">4927708</pub-id>-->
<pub-id pub-id-type="pmid">27285851</pub-id></mixed-citation>
</ref>
<ref id="ref-39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Noh</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name></person-group>:
<article-title>Current advances in retroviral gene therapy.</article-title>
<source/><italic>Curr Gene Ther.</italic>
<year>2011</year>;<volume>11</volume>(<issue>3</issue>):<fpage>218</fpage>–<lpage>28</lpage>.
<pub-id pub-id-type="doi">10.2174/156652311795684740</pub-id>
<!--<pub-id pub-id-type="pmcid">3182074</pub-id>-->
<pub-id pub-id-type="pmid">21453283</pub-id></mixed-citation>
</ref>
<ref id="ref-40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dropulić</surname><given-names>B</given-names></name></person-group>:
<article-title>Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>2011</year>;<volume>22</volume>(<issue>6</issue>):<fpage>649</fpage>–<lpage>57</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.2011.058</pub-id>
<pub-id pub-id-type="pmid">21486177</pub-id></mixed-citation>
</ref>
<ref id="ref-41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mátrai</surname><given-names>J</given-names></name><name><surname>Chuah</surname><given-names>MK</given-names></name><name><surname>VandenDriessche</surname><given-names>T</given-names></name></person-group>:
<article-title>Recent advances in lentiviral vector development and applications.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2010</year>;<volume>18</volume>(<issue>3</issue>):<fpage>477</fpage>–<lpage>90</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2009.319</pub-id>
<!--<pub-id pub-id-type="pmcid">2839421</pub-id>-->
<pub-id pub-id-type="pmid">20087315</pub-id></mixed-citation>
</ref>
<ref id="ref-42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>Inhibition of HIV-1 infection of primary CD4
<sup>+</sup> T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.</article-title>
<source/><italic>J Gen Virol.</italic>
<year>2015</year>;<volume>96</volume>(<issue>8</issue>):<fpage>2381</fpage>–<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1099/vir.0.000139</pub-id>
<pub-id pub-id-type="pmid">25854553</pub-id></mixed-citation>
</ref>
<ref id="ref-43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gwiazda</surname><given-names>KS</given-names></name><name><surname>Grier</surname><given-names>AE</given-names></name><name><surname>Sahni</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2016</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1570</fpage>–<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2016.105</pub-id>
<!--<pub-id pub-id-type="pmcid">5113096</pub-id>-->
<pub-id pub-id-type="pmid">27203437</pub-id></mixed-citation>
</ref>
<ref id="ref-44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>St George</surname><given-names>JA</given-names></name></person-group>:
<article-title>Gene therapy progress and prospects: adenoviral vectors.</article-title>
<source/><italic>Gene Ther.</italic>
<year>2003</year>;<volume>10</volume>(<issue>14</issue>):<fpage>1135</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.gt.3302071</pub-id>
<pub-id pub-id-type="pmid">12833122</pub-id></mixed-citation>
</ref>
<ref id="ref-45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kochanek</surname><given-names>S</given-names></name></person-group>:
<article-title>High-capacity adenoviral vectors for gene transfer and somatic gene therapy.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>1999</year>;<volume>10</volume>(<issue>15</issue>):<fpage>2451</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1089/10430349950016807</pub-id>
<pub-id pub-id-type="pmid">10543611</pub-id></mixed-citation>
</ref>
<ref id="ref-46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lusky</surname><given-names>M</given-names></name></person-group>:
<article-title>Good manufacturing practice production of adenoviral vectors for clinical trials.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>2005</year>;<volume>16</volume>(<issue>3</issue>):<fpage>281</fpage>–<lpage>91</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.2005.16.281</pub-id>
<pub-id pub-id-type="pmid">15812223</pub-id></mixed-citation>
</ref>
<ref id="ref-47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Volpers</surname><given-names>C</given-names></name><name><surname>Kochanek</surname><given-names>S</given-names></name></person-group>:
<article-title>Adenoviral vectors for gene transfer and therapy.</article-title>
<source/><italic>J Gene Med.</italic>
<year>2004</year>;<volume>6</volume>(<issue>Suppl 1</issue>):<fpage>S164</fpage>–<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1002/jgm.496</pub-id>
<pub-id pub-id-type="pmid">14978759</pub-id></mixed-citation>
</ref>
<ref id="ref-48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McConnell</surname><given-names>MJ</given-names></name><name><surname>Imperiale</surname><given-names>MJ</given-names></name></person-group>:
<article-title>Biology of adenovirus and its use as a vector for gene therapy.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>2004</year>;<volume>15</volume>(<issue>11</issue>):<fpage>1022</fpage>–<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.2004.15.1022</pub-id>
<pub-id pub-id-type="pmid">15610603</pub-id></mixed-citation>
</ref>
<ref id="ref-49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Bell</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2016</year>;<volume>34</volume>(<issue>3</issue>):<fpage>334</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3469</pub-id>
<!--<pub-id pub-id-type="pmcid">4786489</pub-id>-->
<pub-id pub-id-type="pmid">26829317</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726111852">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chew</surname><given-names>WL</given-names></name><name><surname>Tabebordbar</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>JK</given-names></name><etal></etal></person-group>:
<article-title>A multifunctional AAV-CRISPR-Cas9 and its host response.</article-title>
<source/><italic>Nat Methods.</italic>
<year>2016</year>;<volume>13</volume>(<issue>10</issue>):<fpage>868</fpage>–<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1038/nmeth.3993</pub-id>
<!--<pub-id pub-id-type="pmcid">5374744</pub-id>-->
<pub-id pub-id-type="pmid">27595405</pub-id></mixed-citation>
</ref>
<ref id="ref-51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>During</surname><given-names>MJ</given-names></name></person-group>:
<article-title>Adeno-associated virus as a gene delivery system.</article-title>
<source/><italic>Adv Drug Deliv Rev.</italic>
<year>1997</year>;<volume>27</volume>(<issue>1</issue>):<fpage>83</fpage>–<lpage>94</lpage>.
<pub-id pub-id-type="doi">10.1016/S0169-409X(97)00024-0</pub-id>
<pub-id pub-id-type="pmid">10837553</pub-id></mixed-citation>
</ref>
<ref id="ref-52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotterman</surname><given-names>MA</given-names></name><name><surname>Schaffer</surname><given-names>DV</given-names></name></person-group>:
<article-title>Engineering adeno-associated viruses for clinical gene therapy.</article-title>
<source/><italic>Nat Rev Genet.</italic>
<year>2014</year>;<volume>15</volume>(<issue>7</issue>):<fpage>445</fpage>–<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.1038/nrg3742</pub-id>
<!--<pub-id pub-id-type="pmcid">4393649</pub-id>-->
<pub-id pub-id-type="pmid">24840552</pub-id></mixed-citation>
</ref>
<ref id="ref-53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Airenne</surname><given-names>KJ</given-names></name><name><surname>Hu</surname><given-names>YC</given-names></name><name><surname>Kost</surname><given-names>TA</given-names></name><etal></etal></person-group>:
<article-title>Baculovirus: an insect-derived vector for diverse gene transfer applications.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2013</year>;<volume>21</volume>(<issue>4</issue>):<fpage>739</fpage>–<lpage>49</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2012.286</pub-id>
<!--<pub-id pub-id-type="pmcid">3616530</pub-id>-->
<pub-id pub-id-type="pmid">23439502</pub-id></mixed-citation>
</ref>
<ref id="ref-54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tabebordbar</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>JKW</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> gene editing in dystrophic mouse muscle and muscle stem cells.</article-title>
<source/><italic>Science.</italic>
<year>2016</year>;<volume>351</volume>(<issue>6271</issue>):<fpage>407</fpage>–<lpage>11</lpage>.
<pub-id pub-id-type="doi">10.1126/science.aad5177</pub-id>
<!--<pub-id pub-id-type="pmcid">4924477</pub-id>-->
<pub-id pub-id-type="pmid">26721686</pub-id></mixed-citation>
</ref>
<ref id="ref-55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nelson</surname><given-names>CE</given-names></name><name><surname>Hakim</surname><given-names>CH</given-names></name><name><surname>Ousterout</surname><given-names>DG</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.</article-title>
<source/><italic>Science.</italic>
<year>2016</year>;<volume>351</volume>(<issue>6271</issue>):<fpage>403</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1126/science.aad5143</pub-id>
<!--<pub-id pub-id-type="pmcid">4883596</pub-id>-->
<pub-id pub-id-type="pmid">26721684</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726050661">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Long</surname><given-names>C</given-names></name><name><surname>Amoasii</surname><given-names>L</given-names></name><name><surname>Mireault</surname><given-names>AA</given-names></name><etal></etal></person-group>:
<article-title>Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.</article-title>
<source/><italic>Science.</italic>
<year>2016</year>;<volume>351</volume>(<issue>6271</issue>):<fpage>400</fpage>–<lpage>3</lpage>.
<pub-id pub-id-type="doi">10.1126/science.aad5725</pub-id>
<!--<pub-id pub-id-type="pmcid">4760628</pub-id>-->
<pub-id pub-id-type="pmid">26721683</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726050662">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bengtsson</surname><given-names>NE</given-names></name><name><surname>Hall</surname><given-names>JK</given-names></name><name><surname>Odom</surname><given-names>GL</given-names></name><etal></etal></person-group>:
<article-title>Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2017</year>;<volume>8</volume>: 14454.
<pub-id pub-id-type="doi">10.1038/ncomms14454</pub-id>
<!--<pub-id pub-id-type="pmcid">5316861</pub-id>-->
<pub-id pub-id-type="pmid">28195574</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727304044">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruan</surname><given-names>GX</given-names></name><name><surname>Barry</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2017</year>;<volume>25</volume>(<issue>2</issue>):<fpage>331</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymthe.2016.12.006</pub-id>
<!--<pub-id pub-id-type="pmcid">5368591</pub-id>-->
<pub-id pub-id-type="pmid">28109959</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727229707">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hung</surname><given-names>SS</given-names></name><name><surname>Chrysostomou</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells
<italic>In vivo</italic>.</article-title>
<source/><italic>Invest Ophthalmol Vis Sci.</italic>
<year>2016</year>;<volume>57</volume>(<issue>7</issue>):<fpage>3470</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1167/iovs.16-19316</pub-id>
<pub-id pub-id-type="pmid">27367513</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726496362">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Mookherjee</surname><given-names>S</given-names></name><name><surname>Chaitankar</surname><given-names>V</given-names></name><etal></etal></person-group>:
<article-title>
<italic>Nrl</italic> knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2017</year>;<volume>8</volume>: 14716.
<pub-id pub-id-type="doi">10.1038/ncomms14716</pub-id>
<!--<pub-id pub-id-type="pmcid">5355895</pub-id>-->
<pub-id pub-id-type="pmid">28291770</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727401032">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>CQ</given-names></name><name><surname>Dorkin</surname><given-names>JR</given-names></name><etal></etal></person-group>:
<article-title>Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components
<italic>in vivo</italic>.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2016</year>;<volume>34</volume>(<issue>3</issue>):<fpage>328</fpage>–<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3471</pub-id>
<!--<pub-id pub-id-type="pmcid">5423356</pub-id>-->
<pub-id pub-id-type="pmid">26829318</pub-id></mixed-citation>
</ref>
<ref id="ref-62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.</article-title>
<source/><italic>Cell Res.</italic>
<year>2016</year>;<volume>26</volume>(<issue>10</issue>):<fpage>1099</fpage>–<lpage>111</lpage>.
<pub-id pub-id-type="doi">10.1038/cr.2016.101</pub-id>
<!--<pub-id pub-id-type="pmcid">5113300</pub-id>-->
<pub-id pub-id-type="pmid">27573176</pub-id></mixed-citation>
</ref>
<ref id="ref-63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carroll</surname><given-names>KJ</given-names></name><name><surname>Makarewich</surname><given-names>CA</given-names></name><name><surname>McAnally</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2016</year>;<volume>113</volume>(<issue>2</issue>):<fpage>338</fpage>–<lpage>43</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1523918113</pub-id>
<!--<pub-id pub-id-type="pmcid">4720342</pub-id>-->
<pub-id pub-id-type="pmid">26719419</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726048045">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johansen</surname><given-names>AK</given-names></name><name><surname>Molenaar</surname><given-names>B</given-names></name><name><surname>Versteeg</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.</article-title>
<source/><italic>Circ Res.</italic>
<year>2017</year>;<volume>121</volume>(<issue>10</issue>):<fpage>1168</fpage>–<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310370</pub-id>
<pub-id pub-id-type="pmid">28851809</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/730126996">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>CRISPR-Cas9 knockin mice for genome editing and cancer modeling.</article-title>
<source/><italic>Cell.</italic>
<year>2014</year>;<volume>159</volume>(<issue>2</issue>):<fpage>440</fpage>–<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2014.09.014</pub-id>
<!--<pub-id pub-id-type="pmcid">4265475</pub-id>-->
<pub-id pub-id-type="pmid">25263330</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718892278">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kleinstiver</surname><given-names>BP</given-names></name><name><surname>Prew</surname><given-names>MS</given-names></name><name><surname>Tsai</surname><given-names>SQ</given-names></name><etal></etal></person-group>:
<article-title>Engineered CRISPR-Cas9 nucleases with altered PAM specificities.</article-title>
<source/><italic>Nature.</italic>
<year>2015</year>;<volume>523</volume>(<issue>7561</issue>):<fpage>481</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1038/nature14592</pub-id>
<!--<pub-id pub-id-type="pmcid">4540238</pub-id>-->
<pub-id pub-id-type="pmid">26098369</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725579684">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishimasu</surname><given-names>H</given-names></name><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><etal></etal></person-group>:
<article-title>Crystal structure of Cas9 in complex with guide RNA and target DNA.</article-title>
<source/><italic>Cell.</italic>
<year>2014</year>;<volume>156</volume>(<issue>5</issue>):<fpage>935</fpage>–<lpage>49</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2014.02.001</pub-id>
<!--<pub-id pub-id-type="pmcid">4139937</pub-id>-->
<pub-id pub-id-type="pmid">24529477</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718277941">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tervo</surname><given-names>DG</given-names></name><name><surname>Hwang</surname><given-names>B</given-names></name><name><surname>Viswanathan</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons.</article-title>
<source/><italic>Neuron.</italic>
<year>2016</year>;<volume>92</volume>(<issue>2</issue>):<fpage>372</fpage>–<lpage>82</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuron.2016.09.021</pub-id>
<pub-id pub-id-type="pmid">27720486</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726829911">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kemaladewi</surname><given-names>DU</given-names></name><name><surname>Maino</surname><given-names>E</given-names></name><name><surname>Hyatt</surname><given-names>E</given-names></name><etal></etal></person-group>:
<article-title>Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism.</article-title>
<source/><italic>Nat Med.</italic>
<year>2017</year>;<volume>23</volume>(<issue>8</issue>):<fpage>984</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/nm.4367</pub-id>
<pub-id pub-id-type="pmid">28714989</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727815117">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>El Refaey</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.</article-title>
<source/><italic>Circ Res.</italic>
<year>2017</year>;<volume>121</volume>(<issue>8</issue>):<fpage>923</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310996</pub-id>
<!--<pub-id pub-id-type="pmcid">5623072</pub-id>-->
<pub-id pub-id-type="pmid">28790199</pub-id></mixed-citation>
</ref>
<ref id="ref-71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohmori</surname><given-names>T</given-names></name><name><surname>Nagao</surname><given-names>Y</given-names></name><name><surname>Mizukami</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.</article-title>
<source/><italic>Sci Rep.</italic>
<year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>4159</fpage>.
<pub-id pub-id-type="doi">10.1038/s41598-017-04625-5</pub-id>
<!--<pub-id pub-id-type="pmcid">5482879</pub-id>-->
<pub-id pub-id-type="pmid">28646206</pub-id></mixed-citation>
</ref>
<ref id="ref-72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vivo</italic> Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2017</year>;<volume>25</volume>(<issue>5</issue>):<fpage>1168</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.03.012</pub-id>
<!--<pub-id pub-id-type="pmcid">5417847</pub-id>-->
<pub-id pub-id-type="pmid">28366764</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727471680">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Sander</surname><given-names>JD</given-names></name><name><surname>Reyon</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Improving CRISPR-Cas nuclease specificity using truncated guide RNAs.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2014</year>;<volume>32</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>84</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.2808</pub-id>
<!--<pub-id pub-id-type="pmcid">3988262</pub-id>-->
<pub-id pub-id-type="pmid">24463574</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718252428">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>KM</given-names></name><name><surname>Pattanayak</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>DB</given-names></name><etal></etal></person-group>:
<article-title>Small molecule-triggered Cas9 protein with improved genome-editing specificity.</article-title>
<source/><italic>Nat Chem Biol.</italic>
<year>2015</year>;<volume>11</volume>(<issue>5</issue>):<fpage>316</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1038/nchembio.1793</pub-id>
<!--<pub-id pub-id-type="pmcid">4402137</pub-id>-->
<pub-id pub-id-type="pmid">25848930</pub-id></mixed-citation>
</ref>
<ref id="ref-75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>Small molecules enhance CRISPR genome editing in pluripotent stem cells.</article-title>
<source/><italic>Cell Stem Cell.</italic>
<year>2015</year>;<volume>16</volume>(<issue>2</issue>):<fpage>142</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.stem.2015.01.003</pub-id>
<!--<pub-id pub-id-type="pmcid">4461869</pub-id>-->
<pub-id pub-id-type="pmid">25658371</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725340884">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monteys</surname><given-names>AM</given-names></name><name><surname>Ebanks</surname><given-names>SA</given-names></name><name><surname>Keiser</surname><given-names>MS</given-names></name><etal></etal></person-group>:
<article-title>CRISPR/Cas9 Editing of the Mutant Huntingtin Allele
<italic>In Vitro</italic> and
<italic>In Vivo</italic>.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2017</year>;<volume>25</volume>(<issue>1</issue>):<fpage>12</fpage>–<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymthe.2016.11.010</pub-id>
<!--<pub-id pub-id-type="pmcid">5363210</pub-id>-->
<pub-id pub-id-type="pmid">28129107</pub-id></mixed-citation>
</ref>
<ref id="ref-77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jarrett</surname><given-names>KE</given-names></name><name><surname>Lee</surname><given-names>CM</given-names></name><name><surname>Yeh</surname><given-names>YH</given-names></name><etal></etal></person-group>:
<article-title>Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease.</article-title>
<source/><italic>Sci Rep.</italic>
<year>2017</year>;<volume>7</volume>: 44624.
<pub-id pub-id-type="doi">10.1038/srep44624</pub-id>
<!--<pub-id pub-id-type="pmcid">5353616</pub-id>-->
<pub-id pub-id-type="pmid">28300165</pub-id></mixed-citation>
</ref>
<ref id="ref-78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>VanDusen</surname><given-names>NJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Analysis of Cardiac Myocyte Maturation Using CASAAV, a Platform for Rapid Dissection of Cardiac Myocyte Gene Function
<italic>In Vivo</italic>.</article-title>
<source/><italic>Circ Res.</italic>
<year>2017</year>;<volume>120</volume>(<issue>12</issue>):<fpage>1874</fpage>–<lpage>88</lpage>.
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310283</pub-id>
<!--<pub-id pub-id-type="pmcid">5466492</pub-id>-->
<pub-id pub-id-type="pmid">28356340</pub-id></mixed-citation>
</ref>
<ref id="ref-79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chow</surname><given-names>RD</given-names></name><name><surname>Guzman</surname><given-names>CD</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>AAV-mediated direct
<italic>in vivo</italic> CRISPR screen identifies functional suppressors in glioblastoma.</article-title>
<source/><italic>Nat Neurosci.</italic>
<year>2017</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1329</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1038/nn.4620</pub-id>
<!--<pub-id pub-id-type="pmcid">5614841</pub-id>-->
<pub-id pub-id-type="pmid">28805815</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/728639298">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murlidharan</surname><given-names>G</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector.</article-title>
<source/><italic>Mol Ther Nucleic Acids.</italic>
<year>2016</year>;<volume>5</volume>(<issue>7</issue>):<fpage>e338</fpage>.
<pub-id pub-id-type="doi">10.1038/mtna.2016.49</pub-id>
<!--<pub-id pub-id-type="pmcid">5330941</pub-id>-->
<pub-id pub-id-type="pmid">27434683</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726593736">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Solis</surname><given-names>CA</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Holehonnur</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>The Development of a Viral Mediated CRISPR/Cas9 System with Doxycycline Dependent gRNA Expression for Inducible
<italic>In vitro</italic> and
<italic>In vivo</italic> Genome Editing.</article-title>
<source/><italic>Front Mol Neurosci.</italic>
<year>2016</year>;<volume>9</volume>:<fpage>70</fpage>.
<pub-id pub-id-type="doi">10.3389/fnmol.2016.00070</pub-id>
<!--<pub-id pub-id-type="pmcid">4988984</pub-id>-->
<pub-id pub-id-type="pmid">27587996</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726705702">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>J</given-names></name><name><surname>Mikuni</surname><given-names>T</given-names></name><name><surname>Yasuda</surname><given-names>R</given-names></name></person-group>:
<article-title>Virus-Mediated Genome Editing via Homology-Directed Repair in Mitotic and Postmitotic Cells in Mammalian Brain.</article-title>
<source/><italic>Neuron.</italic>
<year>2017</year>;<volume>96</volume>(<issue>4</issue>):<fpage>755</fpage>–<lpage>768.e5</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.10.004</pub-id>
<!--<pub-id pub-id-type="pmcid">5691606</pub-id>-->
<pub-id pub-id-type="pmid">29056297</pub-id></mixed-citation>
</ref>
<ref id="ref-83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group>:
<article-title>Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus.</article-title>
<source/><italic>Neuroscience.</italic>
<year>2017</year>;<volume>363</volume>:<fpage>11</fpage>–<lpage>25</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.08.053</pub-id>
<pub-id pub-id-type="pmid">28888955</pub-id></mixed-citation>
</ref>
<ref id="ref-84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><etal></etal></person-group>:
<article-title>Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase.</article-title>
<source/><italic>Mol Neurobiol.</italic>
<year>2016</year>;<fpage>1</fpage>–<lpage>14</lpage>.
<pub-id pub-id-type="doi">10.1007/s12035-016-0335-z</pub-id>
<pub-id pub-id-type="pmid">25394384</pub-id></mixed-citation>
</ref>
<ref id="ref-85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><etal></etal></person-group>:
<article-title>Genome editing abrogates angiogenesis
<italic>in vivo</italic>.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>112</fpage>.
<pub-id pub-id-type="doi">10.1038/s41467-017-00140-3</pub-id>
<!--<pub-id pub-id-type="pmcid">5524639</pub-id>-->
<pub-id pub-id-type="pmid">28740073</pub-id></mixed-citation>
</ref>
<ref id="ref-86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>R</given-names></name><name><surname>Bella</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Excision of HIV-1 DNA by gene editing: a proof-of-concept
<italic>in vivo</italic> study.</article-title>
<source/><italic>Gene Ther.</italic>
<year>2016</year>;<volume>23</volume>(<issue>8–9</issue>):<fpage>690</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1038/gt.2016.41</pub-id>
<!--<pub-id pub-id-type="pmcid">4974122</pub-id>-->
<pub-id pub-id-type="pmid">27194423</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726366657">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grimm</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>
<italic>In vitro</italic> and
<italic>in vivo</italic> gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.</article-title>
<source/><italic>J Virol.</italic>
<year>2008</year>;<volume>82</volume>(<issue>12</issue>):<fpage>5887</fpage>–<lpage>911</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.00254-08</pub-id>
<!--<pub-id pub-id-type="pmcid">2395137</pub-id>-->
<pub-id pub-id-type="pmid">18400866</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1116360">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>H</given-names></name><name><surname>Mizushima</surname><given-names>T</given-names></name><name><surname>Chijiwa</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>Efficient production of recombinant adeno-associated viral vector, serotype DJ/8, carrying the GFP gene.</article-title>
<source/><italic>Virus Res.</italic>
<year>2017</year>;<volume>238</volume>:<fpage>63</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.virusres.2017.05.017</pub-id>
<pub-id pub-id-type="pmid">28571759</pub-id></mixed-citation>
</ref>
<ref id="ref-89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Takino</surname><given-names>N</given-names></name><name><surname>Miyauchi</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice.</article-title>
<source/><italic>Biomed Res Int.</italic>
<year>2013</year>;<volume>2013</volume>: 974819.
<pub-id pub-id-type="doi">10.1155/2013/974819</pub-id>
<!--<pub-id pub-id-type="pmcid">3671507</pub-id>-->
<pub-id pub-id-type="pmid">23762870</pub-id></mixed-citation>
</ref>
<ref id="ref-90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCarty</surname><given-names>DM</given-names></name><name><surname>Monahan</surname><given-names>PE</given-names></name><name><surname>Samulski</surname><given-names>RJ</given-names></name></person-group>:
<article-title>Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.</article-title>
<source/><italic>Gene Ther.</italic>
<year>2001</year>;<volume>8</volume>(<issue>16</issue>):<fpage>1248</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.gt.3301514</pub-id>
<pub-id pub-id-type="pmid">11509958</pub-id></mixed-citation>
</ref>
<ref id="ref-91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><etal></etal></person-group>:
<article-title>The EF-1α promoter maintains high-level transgene expression from episomal vectors in transfected CHO-K1 cells.</article-title>
<source/><italic>J Cell Mol Med.</italic>
<year>2017</year>;<volume>21</volume>(<issue>11</issue>):<fpage>3044</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1111/jcmm.13216</pub-id>
<!--<pub-id pub-id-type="pmcid">5661254</pub-id>-->
<pub-id pub-id-type="pmid">28557288</pub-id></mixed-citation>
</ref>
<ref id="ref-92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teschendorf</surname><given-names>C</given-names></name><name><surname>Warrington</surname><given-names>KH</given-names><suffix>Jr</suffix></name><name><surname>Siemann</surname><given-names>DW</given-names></name><etal></etal></person-group>:
<article-title>Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus.</article-title>
<source/><italic>Anticancer Res.</italic>
<year>2002</year>;<volume>22</volume>(<issue>6A</issue>):<fpage>3325</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="pmid">12530082</pub-id></mixed-citation>
</ref>
<ref id="ref-93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>Sonntag</surname><given-names>KC</given-names></name><etal></etal></person-group>:
<article-title>Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines.</article-title>
<source/><italic>Stem Cells.</italic>
<year>2002</year>;<volume>20</volume>(<issue>2</issue>):<fpage>139</fpage>–<lpage>45</lpage>.
<pub-id pub-id-type="doi">10.1634/stemcells.20-2-139</pub-id>
<!--<pub-id pub-id-type="pmcid">2615228</pub-id>-->
<pub-id pub-id-type="pmid">11897870</pub-id></mixed-citation>
</ref>
<ref id="ref-94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roelz</surname><given-names>R</given-names></name><name><surname>Pilz</surname><given-names>IH</given-names></name><name><surname>Mutschler</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells.</article-title>
<source/><italic>Exp Hematol.</italic>
<year>2010</year>;<volume>38</volume>(<issue>9</issue>):<fpage>792</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.exphem.2010.05.005</pub-id>
<pub-id pub-id-type="pmid">20685233</pub-id></mixed-citation>
</ref>
<ref id="ref-95">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mäkinen</surname><given-names>PI</given-names></name><name><surname>Koponen</surname><given-names>JK</given-names></name><name><surname>Kärkkäinen</surname><given-names>AM</given-names></name><etal></etal></person-group>:
<article-title>Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain.</article-title>
<source/><italic>J Gene Med.</italic>
<year>2006</year>;<volume>8</volume>(<issue>4</issue>):<fpage>433</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1002/jgm.860</pub-id>
<pub-id pub-id-type="pmid">16389634</pub-id></mixed-citation>
</ref>
<ref id="ref-96">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>CP</given-names></name><name><surname>Wu</surname><given-names>TH</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><etal></etal></person-group>:
<article-title>Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>2013</year>;<volume>24</volume>(<issue>8</issue>):<fpage>739</fpage>–<lpage>50</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.2012.239</pub-id>
<!--<pub-id pub-id-type="pmcid">3747597</pub-id>-->
<pub-id pub-id-type="pmid">23829557</pub-id></mixed-citation>
</ref>
<ref id="ref-97">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larson</surname><given-names>MH</given-names></name><name><surname>Gilbert</surname><given-names>LA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal></etal></person-group>:
<article-title>CRISPR interference (CRISPRi) for sequence-specific control of gene expression.</article-title>
<source/><italic>Nat Protoc.</italic>
<year>2013</year>;<volume>8</volume>(<issue>11</issue>):<fpage>2180</fpage>–<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1038/nprot.2013.132</pub-id>
<!--<pub-id pub-id-type="pmcid">3922765</pub-id>-->
<pub-id pub-id-type="pmid">24136345</pub-id></mixed-citation>
</ref>
<ref id="ref-98">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranganathan</surname><given-names>V</given-names></name><name><surname>Wahlin</surname><given-names>K</given-names></name><name><surname>Maruotti</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Expansion of the CRISPR-Cas9 genome targeting space through the use of H1 promoter-expressed guide RNAs.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2014</year>;<volume>5</volume>:<fpage>4516</fpage>.
<pub-id pub-id-type="doi">10.1038/ncomms5516</pub-id>
<!--<pub-id pub-id-type="pmcid">4133144</pub-id>-->
<pub-id pub-id-type="pmid">25105359</pub-id></mixed-citation>
</ref>
<ref id="ref-99">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vidigal</surname><given-names>JA</given-names></name><name><surname>Ventura</surname><given-names>A</given-names></name></person-group>:
<article-title>Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2015</year>;<volume>6</volume>:<fpage>8083</fpage>.
<pub-id pub-id-type="doi">10.1038/ncomms9083</pub-id>
<!--<pub-id pub-id-type="pmcid">4544769</pub-id>-->
<pub-id pub-id-type="pmid">26278926</pub-id></mixed-citation>
</ref>
<ref id="ref-100">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saraiva</surname><given-names>J</given-names></name><name><surname>Nobre</surname><given-names>RJ</given-names></name><name><surname>Pereira de Almeida</surname><given-names>L</given-names></name></person-group>:
<article-title>Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.</article-title>
<source/><italic>J Control Release.</italic>
<year>2016</year>;<volume>241</volume>:<fpage>94</fpage>–<lpage>109</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jconrel.2016.09.011</pub-id>
<pub-id pub-id-type="pmid">27637390</pub-id></mixed-citation>
</ref>
<ref id="ref-101">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vagner</surname><given-names>T</given-names></name><name><surname>Dvorzhak</surname><given-names>A</given-names></name><name><surname>Wójtowicz</surname><given-names>AM</given-names></name><etal></etal></person-group>:
<article-title>Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI Huntington's disease mice.</article-title>
<source/><italic>Mol Cell Neurosci.</italic>
<year>2016</year>;<volume>77</volume>:<fpage>76</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1016/j.mcn.2016.10.007</pub-id>
<pub-id pub-id-type="pmid">27989734</pub-id></mixed-citation>
</ref>
<ref id="ref-102">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanguy</surname><given-names>Y</given-names></name><name><surname>Biferi</surname><given-names>MG</given-names></name><name><surname>Besse</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice.</article-title>
<source/><italic>Front Mol Neurosci.</italic>
<year>2015</year>;<volume>8</volume>:<fpage>36</fpage>.
<pub-id pub-id-type="doi">10.3389/fnmol.2015.00036</pub-id>
<!--<pub-id pub-id-type="pmcid">4516891</pub-id>-->
<pub-id pub-id-type="pmid">26283910</pub-id></mixed-citation>
</ref>
<ref id="ref-103">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D</given-names></name></person-group>:
<article-title>CRISPR gene-editing tested in a person for the first time.</article-title>
<source/><italic>Nature.</italic>
<year>2016</year>;<volume>539</volume>(<issue>7630</issue>):<fpage>479</fpage>.
<pub-id pub-id-type="doi">10.1038/nature.2016.20988</pub-id>
<pub-id pub-id-type="pmid">27882996</pub-id></mixed-citation>
</ref>
<ref id="ref-104">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D</given-names></name></person-group>:
<article-title>Chinese scientists to pioneer first human CRISPR trial.</article-title>
<source/><italic>Nature.</italic>
<year>2016</year>;<volume>535</volume>(<issue>7613</issue>):<fpage>476</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/nature.2016.20302</pub-id>
<pub-id pub-id-type="pmid">27466105</pub-id></mixed-citation>
</ref>
<ref id="ref-105">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Costa</surname><given-names>R</given-names></name><name><surname>Carneiro</surname><given-names>BA</given-names></name><name><surname>Agulnik</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.</article-title>
<source/><italic>Oncotarget.</italic>
<year>2017</year>;<volume>8</volume>(<issue>5</issue>):<fpage>8910</fpage>–<lpage>20</lpage>.
<pub-id pub-id-type="doi">10.18632/oncotarget.13315</pub-id>
<!--<pub-id pub-id-type="pmcid">5352453</pub-id>-->
<pub-id pub-id-type="pmid">27852042</pub-id></mixed-citation>
</ref>
<ref id="ref-106">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Arai</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.</article-title>
<source/><italic>Oncotarget.</italic>
<year>2016</year>;<volume>7</volume>(<issue>45</issue>):<fpage>73068</fpage>–<lpage>79</lpage>.
<pub-id pub-id-type="doi">10.18632/oncotarget.12230</pub-id>
<!--<pub-id pub-id-type="pmcid">5341964</pub-id>-->
<pub-id pub-id-type="pmid">27683031</pub-id></mixed-citation>
</ref>
<ref id="ref-107">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Mah</surname><given-names>CS</given-names></name><etal></etal></person-group>:
<article-title>Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2008</year>;<volume>105</volume>(<issue>22</issue>):<fpage>7827</fpage>–<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.0802866105</pub-id>
<!--<pub-id pub-id-type="pmcid">2402387</pub-id>-->
<pub-id pub-id-type="pmid">18511559</pub-id></mixed-citation>
</ref>
<ref id="ref-108">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><etal></etal></person-group>:
<article-title>Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses.</article-title>
<source/><italic>Hum Gene Ther Methods.</italic>
<year>2016</year>;<volume>27</volume>(<issue>4</issue>):<fpage>143</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1089/hgtb.2016.054</pub-id>
<!--<pub-id pub-id-type="pmcid">4991608</pub-id>-->
<pub-id pub-id-type="pmid">27431826</pub-id></mixed-citation>
</ref>
<ref id="ref-109">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq.</article-title>
<source/><italic>Genome Res.</italic>
<year>2016</year>;<volume>26</volume>(<issue>3</issue>):<fpage>406</fpage>–<lpage>15</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.199588.115</pub-id>
<!--<pub-id pub-id-type="pmcid">4772022</pub-id>-->
<pub-id pub-id-type="pmid">26786045</pub-id></mixed-citation>
</ref>
<ref id="ref-110">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells.</article-title>
<source/><italic>Nat Methods.</italic>
<year>2015</year>;<volume>12</volume>(<issue>3</issue>):<fpage>237</fpage>–<lpage>43</lpage>, 1 p following 243.
<pub-id pub-id-type="doi">10.1038/nmeth.3284</pub-id>
<pub-id pub-id-type="pmid">25664545</pub-id></mixed-citation>
</ref>
<ref id="ref-111">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuscu</surname><given-names>C</given-names></name><name><surname>Arslan</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2014</year>;<volume>32</volume>(<issue>7</issue>):<fpage>677</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.2916</pub-id>
<pub-id pub-id-type="pmid">24837660</pub-id></mixed-citation>
</ref>
<ref id="ref-112">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Geen</surname><given-names>H</given-names></name><name><surname>Henry</surname><given-names>IM</given-names></name><name><surname>Bhakta</surname><given-names>MS</given-names></name><etal></etal></person-group>:
<article-title>A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture.</article-title>
<source/><italic>Nucleic Acids Res.</italic>
<year>2015</year>;<volume>43</volume>(<issue>6</issue>):<fpage>3389</fpage>–<lpage>404</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkv137</pub-id>
<!--<pub-id pub-id-type="pmcid">4381059</pub-id>-->
<pub-id pub-id-type="pmid">25712100</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725367733">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-113">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SQ</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><etal></etal></person-group>:
<article-title>GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2015</year>;<volume>33</volume>(<issue>2</issue>):<fpage>187</fpage>–<lpage>97</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3117</pub-id>
<!--<pub-id pub-id-type="pmcid">4320685</pub-id>-->
<pub-id pub-id-type="pmid">25513782</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725275523">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-114">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Grishin</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2014</year>;<volume>5</volume>: 5507.
<pub-id pub-id-type="doi">10.1038/ncomms6507</pub-id>
<!--<pub-id pub-id-type="pmcid">4352754</pub-id>-->
<pub-id pub-id-type="pmid">25425480</pub-id></mixed-citation>
</ref>
<ref id="ref-115">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morgens</surname><given-names>DW</given-names></name><name><surname>Wainberg</surname><given-names>M</given-names></name><name><surname>Boyle</surname><given-names>EA</given-names></name><etal></etal></person-group>:
<article-title>Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2017</year>;<volume>8</volume>: 15178.
<pub-id pub-id-type="doi">10.1038/ncomms15178</pub-id>
<!--<pub-id pub-id-type="pmcid">5424143</pub-id>-->
<pub-id pub-id-type="pmid">28474669</pub-id></mixed-citation>
</ref>
<ref id="ref-116">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cameron</surname><given-names>P</given-names></name><name><surname>Fuller</surname><given-names>CK</given-names></name><name><surname>Donohoue</surname><given-names>PD</given-names></name><etal></etal></person-group>:
<article-title>Mapping the genomic landscape of CRISPR-Cas9 cleavage.</article-title>
<source/><italic>Nat Methods.</italic>
<year>2017</year>;<volume>14</volume>(<issue>6</issue>):<fpage>600</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1038/nmeth.4284</pub-id>
<pub-id pub-id-type="pmid">28459459</pub-id></mixed-citation>
</ref>
<ref id="ref-117">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group>:
<article-title>Implications of human genetic variation in CRISPR-based therapeutic genome editing.</article-title>
<source/><italic>Nat Med.</italic>
<year>2017</year>;<volume>23</volume>(<issue>9</issue>):<fpage>1095</fpage>–<lpage>101</lpage>.
<pub-id pub-id-type="doi">10.1038/nm.4377</pub-id>
<pub-id pub-id-type="pmid">28759051</pub-id></mixed-citation>
</ref>
<ref id="ref-118">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SQ</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Malagon-Lopez</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>CIRCLE-seq: a highly sensitive
<italic>in vitro</italic> screen for genome-wide CRISPR-Cas9 nuclease off-targets.</article-title>
<source/><italic>Nat Methods.</italic>
<year>2017</year>;<volume>14</volume>(<issue>6</issue>):<fpage>607</fpage>–<lpage>14</lpage>.
<pub-id pub-id-type="doi">10.1038/nmeth.4278</pub-id>
<pub-id pub-id-type="pmid">28459458</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727567316">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-119">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><etal></etal></person-group>:
<article-title>Genome-wide target specificities of CRISPR RNA-guided programmable deaminases.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2017</year>;<volume>35</volume>(<issue>5</issue>):<fpage>475</fpage>–<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3852</pub-id>
<pub-id pub-id-type="pmid">28398345</pub-id></mixed-citation>
</ref>
<ref id="ref-120">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koo</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name></person-group>:
<article-title>Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9.</article-title>
<source/><italic>Mol Cells.</italic>
<year>2015</year>;<volume>38</volume>(<issue>6</issue>):<fpage>475</fpage>–<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.14348/molcells.2015.0103</pub-id>
<!--<pub-id pub-id-type="pmcid">4469905</pub-id>-->
<pub-id pub-id-type="pmid">25985872</pub-id></mixed-citation>
</ref>
<ref id="ref-121">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Nelles</surname><given-names>DA</given-names></name><name><surname>Pirie</surname><given-names>E</given-names></name><etal></etal></person-group>:
<article-title>Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.</article-title>
<source/><italic>Cell.</italic>
<year>2017</year>;<volume>170</volume>(<issue>5</issue>):<fpage>899</fpage>–<lpage>912.e10</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2017.07.010</pub-id>
<pub-id pub-id-type="pmid">28803727</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/728639308">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-122">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pinto</surname><given-names>BS</given-names></name><name><surname>Saxena</surname><given-names>T</given-names></name><name><surname>Oliveira</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9.</article-title>
<source/><italic>Mol Cell.</italic>
<year>2017</year>;<volume>68</volume>(<issue>3</issue>):<fpage>479</fpage>–<lpage>490.e5</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2017.09.033</pub-id>
<pub-id pub-id-type="pmid">29056323</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732025728">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-123">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><etal></etal></person-group>:
<article-title>Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration.</article-title>
<source/><italic>Genome Res.</italic>
<year>2017</year>;<volume>27</volume>(<issue>3</issue>):<fpage>419</fpage>–<lpage>26</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.219089.116</pub-id>
<!--<pub-id pub-id-type="pmcid">5340969</pub-id>-->
<pub-id pub-id-type="pmid">28209587</pub-id></mixed-citation>
</ref>
<ref id="ref-124">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nihongaki</surname><given-names>Y</given-names></name><name><surname>Kawano</surname><given-names>F</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><etal></etal></person-group>:
<article-title>Photoactivatable CRISPR-Cas9 for optogenetic genome editing.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2015</year>;<volume>33</volume>(<issue>7</issue>):<fpage>755</fpage>–<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3245</pub-id>
<pub-id pub-id-type="pmid">26076431</pub-id></mixed-citation>
</ref>
<ref id="ref-125">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polstein</surname><given-names>LR</given-names></name><name><surname>Gersbach</surname><given-names>CA</given-names></name></person-group>:
<article-title>A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.</article-title>
<source/><italic>Nat Chem Biol.</italic>
<year>2015</year>;<volume>11</volume>(<issue>3</issue>):<fpage>198</fpage>–<lpage>200</lpage>.
<pub-id pub-id-type="doi">10.1038/nchembio.1753</pub-id>
<!--<pub-id pub-id-type="pmcid">4412021</pub-id>-->
<pub-id pub-id-type="pmid">25664691</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725348560">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-126">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dow</surname><given-names>LE</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name><name><surname>O'Rourke</surname><given-names>KP</given-names></name><etal></etal></person-group>:
<article-title>Inducible
<italic>in vivo</italic> genome editing with CRISPR-Cas9.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2015</year>;<volume>33</volume>(<issue>4</issue>):<fpage>390</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3155</pub-id>
<!--<pub-id pub-id-type="pmcid">4390466</pub-id>-->
<pub-id pub-id-type="pmid">25690852</pub-id></mixed-citation>
</ref>
<ref id="ref-127">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>KI</given-names></name><name><surname>Ramli</surname><given-names>MN</given-names></name><name><surname>Woo</surname><given-names>CW</given-names></name><etal></etal></person-group>:
<article-title>A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing.</article-title>
<source/><italic>Nat Chem Biol.</italic>
<year>2016</year>;<volume>12</volume>(<issue>11</issue>):<fpage>980</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/nchembio.2179</pub-id>
<pub-id pub-id-type="pmid">27618190</pub-id></mixed-citation>
</ref>
<ref id="ref-128">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2014</year>;<volume>5</volume>:<fpage>5393</fpage>.
<pub-id pub-id-type="doi">10.1038/ncomms6393</pub-id>
<pub-id pub-id-type="pmid">25373919</pub-id></mixed-citation>
</ref>
<ref id="ref-129">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>BH</given-names></name><name><surname>Pham</surname><given-names>NT</given-names></name><name><surname>Caraballo</surname><given-names>LD</given-names></name><etal></etal></person-group>:
<article-title>Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2017</year>;<volume>35</volume>(<issue>5</issue>):<fpage>453</fpage>–<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3805</pub-id>
<!--<pub-id pub-id-type="pmcid">5423837</pub-id>-->
<pub-id pub-id-type="pmid">28346402</pub-id></mixed-citation>
</ref>
<ref id="ref-130">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects.</article-title>
<source/><italic>Nat Methods.</italic>
<year>2014</year>;<volume>11</volume>(<issue>4</issue>):<fpage>399</fpage>–<lpage>402</lpage>.
<pub-id pub-id-type="doi">10.1038/nmeth.2857</pub-id>
<pub-id pub-id-type="pmid">24584192</pub-id></mixed-citation>
</ref>
<ref id="ref-131">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases.</article-title>
<source/><italic>Genome Res.</italic>
<year>2014</year>;<volume>24</volume>(<issue>1</issue>):<fpage>132</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.162339.113</pub-id>
<!--<pub-id pub-id-type="pmcid">3875854</pub-id>-->
<pub-id pub-id-type="pmid">24253446</pub-id></mixed-citation>
</ref>
<ref id="ref-132">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><etal></etal></person-group>:
<article-title>Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.</article-title>
<source/><italic>Cell.</italic>
<year>2013</year>;<volume>154</volume>(<issue>6</issue>):<fpage>1380</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2013.08.021</pub-id>
<!--<pub-id pub-id-type="pmcid">3856256</pub-id>-->
<pub-id pub-id-type="pmid">23992846</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718095657">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-133">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guilinger</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>DB</given-names></name><name><surname>Liu</surname><given-names>DR</given-names></name></person-group>:
<article-title>Fusion of catalytically inactive Cas9 to
<italic>FokI</italic> nuclease improves the specificity of genome modification.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2014</year>;<volume>32</volume>(<issue>6</issue>):<fpage>577</fpage>–<lpage>82</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.2909</pub-id>
<!--<pub-id pub-id-type="pmcid">4263420</pub-id>-->
<pub-id pub-id-type="pmid">24770324</pub-id></mixed-citation>
</ref>
<ref id="ref-134">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kleinstiver</surname><given-names>BP</given-names></name><name><surname>Pattanayak</surname><given-names>V</given-names></name><name><surname>Prew</surname><given-names>MS</given-names></name><etal></etal></person-group>:
<article-title>High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.</article-title>
<source/><italic>Nature.</italic>
<year>2016</year>;<volume>529</volume>(<issue>7587</issue>):<fpage>490</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1038/nature16526</pub-id>
<!--<pub-id pub-id-type="pmcid">4851738</pub-id>-->
<pub-id pub-id-type="pmid">26735016</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726058228">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-135">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Slaymaker</surname><given-names>IM</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Zetsche</surname><given-names>B</given-names></name><etal></etal></person-group>:
<article-title>Rationally engineered Cas9 nucleases with improved specificity.</article-title>
<source/><italic>Science.</italic>
<year>2016</year>;<volume>351</volume>(<issue>6268</issue>):<fpage>84</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1126/science.aad5227</pub-id>
<!--<pub-id pub-id-type="pmcid">4714946</pub-id>-->
<pub-id pub-id-type="pmid">26628643</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725974865">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-136">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Dagdas</surname><given-names>YS</given-names></name><name><surname>Kleinstiver</surname><given-names>BP</given-names></name><etal></etal></person-group>:
<article-title>Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.</article-title>
<source/><italic>Nature.</italic>
<year>2017</year>;<volume>550</volume>(<issue>7676</issue>):<fpage>407</fpage>–<lpage>10</lpage>.
<pub-id pub-id-type="doi">10.1038/nature24268</pub-id>
<pub-id pub-id-type="pmid">28931002</pub-id></mixed-citation>
</ref>
<ref id="ref-137">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Komor</surname><given-names>AC</given-names></name><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Packer</surname><given-names>MS</given-names></name><etal></etal></person-group>:
<article-title>Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.</article-title>
<source/><italic>Nature.</italic>
<year>2016</year>;<volume>533</volume>(<issue>7603</issue>):<fpage>420</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1038/nature17946</pub-id>
<!--<pub-id pub-id-type="pmcid">4873371</pub-id>-->
<pub-id pub-id-type="pmid">27096365</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726297168">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-138">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Ryu</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><etal></etal></person-group>:
<article-title>Highly efficient RNA-guided base editing in mouse embryos.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2017</year>;<volume>35</volume>(<issue>5</issue>):<fpage>435</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3816</pub-id>
<pub-id pub-id-type="pmid">28244995</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727363082">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-139">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richardson</surname><given-names>CD</given-names></name><name><surname>Ray</surname><given-names>GJ</given-names></name><name><surname>DeWitt</surname><given-names>MA</given-names></name><etal></etal></person-group>:
<article-title>Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2016</year>;<volume>34</volume>(<issue>3</issue>):<fpage>339</fpage>–<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3481</pub-id>
<pub-id pub-id-type="pmid">26789497</pub-id></mixed-citation>
</ref>
<ref id="ref-140">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency.</article-title>
<source/><italic>Nat Commun.</italic>
<year>2016</year>;<volume>7</volume>:<fpage>10548</fpage>.
<pub-id pub-id-type="doi">10.1038/ncomms10548</pub-id>
<!--<pub-id pub-id-type="pmcid">4738357</pub-id>-->
<pub-id pub-id-type="pmid">26817820</pub-id></mixed-citation>
</ref>
<ref id="ref-141">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Dougan</surname><given-names>SK</given-names></name><name><surname>Truttmann</surname><given-names>MC</given-names></name><etal></etal></person-group>:
<article-title>Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2015</year>;<volume>33</volume>(<issue>5</issue>):<fpage>538</fpage>–<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3190</pub-id>
<!--<pub-id pub-id-type="pmcid">4618510</pub-id>-->
<pub-id pub-id-type="pmid">25798939</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725400493">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-142">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><etal></etal></person-group>:
<article-title>Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2013</year>;<volume>31</volume>(<issue>3</issue>):<fpage>230</fpage>–<lpage>2</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.2507</pub-id>
<pub-id pub-id-type="pmid">23360966</pub-id></mixed-citation>
</ref>
<ref id="ref-143">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hendel</surname><given-names>A</given-names></name><name><surname>Bak</surname><given-names>RO</given-names></name><name><surname>Clark</surname><given-names>JT</given-names></name><etal></etal></person-group>:
<article-title>Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2015</year>;<volume>33</volume>(<issue>9</issue>):<fpage>985</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3290</pub-id>
<!--<pub-id pub-id-type="pmcid">4729442</pub-id>-->
<pub-id pub-id-type="pmid">26121415</pub-id></mixed-citation>
</ref>
<ref id="ref-144">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perez</surname><given-names>AR</given-names></name><name><surname>Pritykin</surname><given-names>Y</given-names></name><name><surname>Vidigal</surname><given-names>JA</given-names></name><etal></etal></person-group>:
<article-title>GuideScan software for improved single and paired CRISPR guide RNA design.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2017</year>;<volume>35</volume>(<issue>4</issue>):<fpage>347</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt.3804</pub-id>
<!--<pub-id pub-id-type="pmcid">5607865</pub-id>-->
<pub-id pub-id-type="pmid">28263296</pub-id></mixed-citation>
</ref>
<ref id="ref-145">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Hino</surname><given-names>K</given-names></name><name><surname>Bono</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites.</article-title>
<source/><italic>Bioinformatics.</italic>
<year>2015</year>;<volume>31</volume>(<issue>7</issue>):<fpage>1120</fpage>–<lpage>3</lpage>.
<pub-id pub-id-type="doi">10.1093/bioinformatics/btu743</pub-id>
<!--<pub-id pub-id-type="pmcid">4382898</pub-id>-->
<pub-id pub-id-type="pmid">25414360</pub-id></mixed-citation>
</ref>
<ref id="ref-146">
<label>146</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name></person-group>:
<article-title>Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases.</article-title>
<source/><italic>Bioinformatics.</italic>
<year>2014</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1473</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1093/bioinformatics/btu048</pub-id>
<!--<pub-id pub-id-type="pmcid">4016707</pub-id>-->
<pub-id pub-id-type="pmid">24463181</pub-id></mixed-citation>
</ref>
<ref id="ref-147">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Tee</surname><given-names>LY</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><etal></etal></person-group>:
<article-title>Off-target Effects in CRISPR/Cas9-mediated Genome Engineering.</article-title>
<source/><italic>Mol Ther Nucleic Acids.</italic>
<year>2015</year>;<volume>4</volume>(<issue>11</issue>):<fpage>e264</fpage>.
<pub-id pub-id-type="doi">10.1038/mtna.2015.37</pub-id>
<!--<pub-id pub-id-type="pmcid">4877446</pub-id>-->
<pub-id pub-id-type="pmid">26575098</pub-id></mixed-citation>
</ref>
<ref id="ref-148">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mockenhaupt</surname><given-names>S</given-names></name><name><surname>Grosse</surname><given-names>S</given-names></name><name><surname>Rupp</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2015</year>;<volume>112</volume>(<issue>30</issue>):<fpage>E4007</fpage>–<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1510476112</pub-id>
<!--<pub-id pub-id-type="pmcid">4522753</pub-id>-->
<pub-id pub-id-type="pmid">26170322</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725633584">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-149">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tay</surname><given-names>FC</given-names></name><name><surname>Lim</surname><given-names>JK</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells.</article-title>
<source/><italic>Adv Drug Deliv Rev.</italic>
<year>2015</year>;<volume>81</volume>:<fpage>117</fpage>–<lpage>27</lpage>.
<pub-id pub-id-type="doi">10.1016/j.addr.2014.05.010</pub-id>
<pub-id pub-id-type="pmid">24859534</pub-id></mixed-citation>
</ref>
<ref id="ref-150">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirosawa</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Parr</surname><given-names>CJC</given-names></name><etal></etal></person-group>:
<article-title>Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch.</article-title>
<source/><italic>Nucleic Acids Res.</italic>
<year>2017</year>;<volume>45</volume>(<issue>13</issue>):<fpage>e118</fpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkx309</pub-id>
<!--<pub-id pub-id-type="pmcid">5570128</pub-id>-->
<pub-id pub-id-type="pmid">28525578</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727626073">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-151">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manning</surname><given-names>WC</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Bland</surname><given-names>MP</given-names></name><etal></etal></person-group>:
<article-title>Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>1998</year>;<volume>9</volume>(<issue>4</issue>):<fpage>477</fpage>–<lpage>85</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.1998.9.4-477</pub-id>
<pub-id pub-id-type="pmid">9525309</pub-id></mixed-citation>
</ref>
<ref id="ref-152">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mingozzi</surname><given-names>F</given-names></name><name><surname>Anguela</surname><given-names>XM</given-names></name><name><surname>Pavani</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>Overcoming preexisting humoral immunity to AAV using capsid decoys.</article-title>
<source/><italic>Sci Transl Med.</italic>
<year>2013</year>;<volume>5</volume>(<issue>194</issue>):<fpage>194ra92</fpage>.
<pub-id pub-id-type="doi">10.1126/scitranslmed.3005795</pub-id>
<!--<pub-id pub-id-type="pmcid">4095828</pub-id>-->
<pub-id pub-id-type="pmid">23863832</pub-id></mixed-citation>
</ref>
<ref id="ref-153">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huttner</surname><given-names>NA</given-names></name><name><surname>Girod</surname><given-names>A</given-names></name><name><surname>Perabo</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.</article-title>
<source/><italic>Gene Ther.</italic>
<year>2003</year>;<volume>10</volume>(<issue>26</issue>):<fpage>2139</fpage>–<lpage>47</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.gt.3302123</pub-id>
<pub-id pub-id-type="pmid">14625569</pub-id></mixed-citation>
</ref>
<ref id="ref-154">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arbetman</surname><given-names>AE</given-names></name><name><surname>Lochrie</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties.</article-title>
<source/><italic>J Virol.</italic>
<year>2005</year>;<volume>79</volume>(<issue>24</issue>):<fpage>15238</fpage>–<lpage>45</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.79.24.15238-15245.2005</pub-id>
<!--<pub-id pub-id-type="pmcid">1316006</pub-id>-->
<pub-id pub-id-type="pmid">16306595</pub-id></mixed-citation>
</ref>
<ref id="ref-155">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maheshri</surname><given-names>N</given-names></name><name><surname>Koerber</surname><given-names>JT</given-names></name><name><surname>Kaspar</surname><given-names>BK</given-names></name><etal></etal></person-group>:
<article-title>Directed evolution of adeno-associated virus yields enhanced gene delivery vectors.</article-title>
<source/><italic>Nat Biotechnol.</italic>
<year>2006</year>;<volume>24</volume>(<issue>2</issue>):<fpage>198</fpage>–<lpage>204</lpage>.
<pub-id pub-id-type="doi">10.1038/nbt1182</pub-id>
<pub-id pub-id-type="pmid">16429148</pub-id></mixed-citation>
</ref>
<ref id="ref-156">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bakondi</surname><given-names>B</given-names></name></person-group>:
<article-title>
<italic>In vivo</italic> versus
<italic>ex vivo</italic> CRISPR therapies for retinal dystrophy.</article-title>
<source/><italic>Expert Rev Ophthalmol.</italic>
<year>2016</year>;<volume>11</volume>(<issue>6</issue>):<fpage>397</fpage>–<lpage>400</lpage>.
<pub-id pub-id-type="doi">10.1080/17469899.2016.1251316</pub-id>
<!--<pub-id pub-id-type="pmcid">5289756</pub-id>-->
<pub-id pub-id-type="pmid">28163772</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727282386">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-157">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grimm</surname><given-names>D</given-names></name><name><surname>Büning</surname><given-names>H</given-names></name></person-group>:
<article-title>Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.</article-title>
<source/><italic>Hum Gene Ther.</italic>
<year>2017</year>;<volume>28</volume>(<issue>11</issue>):<fpage>1075</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="doi">10.1089/hum.2017.172</pub-id>
<pub-id pub-id-type="pmid">28835125</pub-id></mixed-citation>
</ref>
<ref id="ref-158">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paulk</surname><given-names>NK</given-names></name><name><surname>Pekrun</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>E</given-names></name><etal></etal></person-group>:
<article-title>Bioengineered AAV Capsids with Combined High Human Liver Transduction
<italic>In vivo</italic> and Unique Humoral Seroreactivity.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2017</year>; pii: S1525-0016(17)30437-9.
<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.09.021</pub-id>
<pub-id pub-id-type="pmid">29055620</pub-id></mixed-citation>
</ref>
<ref id="ref-159">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tse</surname><given-names>LV</given-names></name><name><surname>Klinc</surname><given-names>KA</given-names></name><name><surname>Madigan</surname><given-names>VJ</given-names></name><etal></etal></person-group>:
<article-title>Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2017</year>;<volume>114</volume>(<issue>24</issue>):<fpage>E4812</fpage>–<lpage>E4821</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1704766114</pub-id>
<!--<pub-id pub-id-type="pmcid">5474820</pub-id>-->
<pub-id pub-id-type="pmid">28559317</pub-id></mixed-citation>
</ref>
<ref id="ref-160">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Albright</surname><given-names>B</given-names></name><etal></etal></person-group>:
<article-title>Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2016</year>;<volume>24</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2015.134</pub-id>
<!--<pub-id pub-id-type="pmcid">4754536</pub-id>-->
<pub-id pub-id-type="pmid">26220272</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>